

1 **1. Study protocol (version 6)**

2

3 **Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus**
4 **tracheal intubation in the initial airway management of out of hospital cardiac arrest**

5



6

7

8 REC No: 14/SC/1219

9 ISRCTN No: 08256118

10 HTA: 12/167/102

11

12 ***Details of Sponsor***

13

14 South Western Ambulance Services NHS Foundation Trust

15 Abbey Court

16 Eagle Way

17 Exeter

18 Devon

19 EX2 7HY

20

21 Tel: 01392 261500

22

23 ***Chief Investigators & Research Team Contact Details***

24

Professor Jonathan Benger -Chief Investigator

Academic Department of Emergency Care
University Hospitals Bristol NHS Foundation Trust
Emergency Department
Bristol Royal Infirmary
Bristol, BS2 8HW

Tel: 0117 3421498

Email: jonathan.benger@uwe.ac.uk

Ms Sarah Black
Trust Headquarters
South Western Ambulance Service NHS Foundation
Trust
Abbey Court
Eagle Way
Exeter, EX2 7HY

Tel: 01392 261640

Email: Sarah.Black@swast.nhs.uk

Dr Sarah Voss
Faculty of Health and Life Sciences
University of the West of England
Glenside Campus (1H14)
Blackberry Hill,
Bristol, BS16 1DD

Tel: 0117 328 8906

Email: Sarah.Voss@uwe.ac.uk

Dr Matthew Thomas
Department of Anaesthesia
University Hospitals Bristol NHS Foundation Trust
Bristol Royal Infirmary
Bristol, BS2 8HW

Tel: 07813 896526

Email: matthew.thomas@UHBristol.nhs.uk

Dr Jerry Nolan
Department of Anaesthesia
Royal United Hospital Bath NHS Trust
Combe Park
Bath, BA1 3NG

Tel: 01225 428331
Email: jerry.nolan@btinternet.com

Professor Barnaby Reeves
Clinical Trials and Evaluation Unit
Research Floor Level 7
Queens Building
Bristol Royal Infirmary
Marlborough Street
Bristol, BS2 8HW

Tel: 01173 423143
Email: Barney.Reeves@bristol.ac.uk

Mr Adrian South
Trust Headquarters
South Western Ambulance Service NHS Foundation
Trust
Abbey Court
Eagle Way
Exeter, EX2 7HY

Tel: 01392 261509
Email: Adrian.South@swast.nhs.uk

Dr Stephen Brett
Dept of Anaesthetics and Intensive Care
Hammersmith Hospital
Du Cane Road,
London W12 0HS

Tel: 0208 383 4521/3143
Email: stephen.brett@imperial.ac.uk

Dr Chris Rogers
Clinical Trials and Evaluation Unit
Research Floor Level 7
Queens Building
Bristol Royal Infirmary
Marlborough Street
Bristol, BS2 8HW

Tel: 01173 422507
Email: Chris.Rogers@bristol.ac.uk

Dr Sarah Wordsworth
Health Economics Research Centre
Department of Public Health
University of Oxford
Old Road Campus
Headington
Oxford, OX3 7LF

Tel: 01865 289268
Email: Sarah.Wordsworth@dph.ox.ac.uk

25

26

27	Table of contents	
28	Glossary / abbreviations.....	5
29	1. Trial summary	6
30	2. Background.....	7
31	2.1 Existing Evidence.....	8
32	2.2 Relevance to the NHS / health policy	8
33	3. Aims and objectives.....	9
34	4. Plan of Investigation	10
35	4.1 Trial schema.....	10
36	4.2 Trial design	10
37	4.3 Key design features to minimise bias.....	11
38	4.3.1 Selection bias/allocation bias (systematic differences between baseline characteristics	
39	of the groups that are compared)	11
40	4.3.2 Performance bias (systematic differences between groups in the care that is provided,	
41	or in exposure to factors other than the interventions of interest).....	11
42	4.3.3 Detection bias (systematic differences between groups in how outcomes are	
43	determined)	11
44	4.3.4 Attrition bias (systematic differences in the availability of outcome data between	
45	groups)	11
46	4.3.5 Reporting bias	12
47	4.4 Trial population	12
48	4.4.1 Inclusion and exclusion criteria for paramedics	12
49	4.4.2 Inclusion and exclusion criteria for patients:.....	12
50	4.5 Trial interventions	14
51	4.5.1 Control group.....	14
52	4.5.2 Intervention group.....	14
53	4.5.3 Aspects of management common to both groups:	14
54	4.6 Primary and secondary outcomes.....	15
55	4.6.1 Primary outcome	15
56	4.6.2 Secondary outcomes	15
57	4.7 Sample size calculation	16
58	5. Trial methods	16
59	5.1 Description of randomisation	16
60	5.2 Procedures to minimise bias	17
61	5.2.1 Selection/allocation bias	17
62	5.2.2 Blinding	17
63	5.3 Research procedures	18
64	5.3.1 Training of Paramedics	18
65	5.3.2 Tracheal Intubation	18
66	5.3.3 Placement of i-gel	18

67	5.3.4	Use of study devices	19
68	5.3.5	Measurements of compression fraction:	19
69	5.4	Duration of treatment period	19
70	5.5	Definition of end of trial	19
71	5.6	Data collection	19
72	5.6.1	Identification of patients with OHCA	21
73	5.6.2	Out of hospital treatment phase (data collection by paramedics)	21
74	5.6.3	Hospital discharge (data collected by hospital staff)	22
75	5.7	Source data	22
76	5.8	Planned recruitment rate	22
77	5.9	Participant recruitment	22
78	5.9.1	Paramedics	22
79	5.9.2	Patients	23
80	5.10	Discontinuation/withdrawal of participants	23
81	5.11	Frequency and duration of follow up	23
82	5.12	Likely rate of loss to follow-up	23
83	5.13	Expenses	23
84	6.	Statistical analyses	23
85	6.1	Plan of analysis	23
86	6.2	Subgroup analyses	24
87	6.3	Frequency of analyses	24
88	6.4	Criteria for the termination of the trial	24
89	6.5	Economic evaluation	25
90	7.	Trial management	26
91	7.1	Day-to-day management	26
92	7.2	Monitoring of sites	26
93	7.2.1	Initiation visit	26
94	7.2.2	Site monitoring	26
95	7.3	Trial Steering Committee and Data Monitoring and Safety Committee	26
96	8.	Safety reporting	27
97	8.1	Additional terms for device trials	27
98	8.2	Expected adverse events	27
99	8.3	Unexpected adverse events	28
100	8.4	Period for recording serious adverse events	28
101	9.	Ethical considerations	28
102	9.1	Review by an NHS Research Ethics Committee (REC)	29
103	9.2	Review by Health Research Authority Confidentiality Advisory Group (CAG)	29
104	9.3	Risks and anticipated benefits	29
105	9.4	Informing potential paramedics of possible benefits and known risks	30

106	9.5	Obtaining informed consent from paramedics	30
107	9.6	Informing potential study participants of possible benefits and known risks	30
108	9.7	Obtaining informed consent from participants	30
109	9.7.1	Consent process for surviving patients with capacity	30
110	9.7.2	Surviving patients who lack capacity	32
111	9.8	Co-enrolment	32
112	10.	Research governance.....	32
113	10.1	Sponsor approval.....	33
114	10.2	NHS approval.....	33
115	10.3	Investigators' responsibilities	33
116	10.4	Monitoring by sponsor	33
117	10.5	Indemnity	33
118	10.6	Clinical Trial Authorisation	33
119	11.	Data protection and participant confidentiality	34
120	11.1	Data protection	34
121	11.2	Data handling, storage and sharing	34
122	11.2.1	Data handling.....	34
123	11.2.2	Data storage.....	34
124	11.2.3	Data sharing.....	34
125	12.	Dissemination of findings	35
126	13.	Amendments to protocol.....	35
127	14.	References	36

128

129 **GLOSSARY / ABBREVIATIONS**

AHA	American Heart Association
BRI	Bristol Royal Infirmary
CAD	Computer aided dispatch
CAG	Confidentiality Advisory Group
CCU	Cardiac care unit
COMET	Core Outcome Measures in Effectiveness Trials
CPR	Cardiopulmonary resuscitation
CRF	Case report form
CTEU	Clinical Trials and Evaluation Unit
DMSC	Data monitoring and safety committee
ECG	Graphical representation of electrical activity of the heart over time, as recorded by an electrocardiograph
ERC	European Resuscitation Council
EQ5D	A standardised instrument for use as a measure of health outcome
GWAS	Great Western Ambulance service

HES	Hospital Episode Statistics
HSFC	Heart and Stroke Foundation of Canada
IAHF	Inter American Heart Foundation
ICH-GCP	International conference for harmonisation of good clinical practice
ICU	Intensive care unit
JRCALC	Joint Royal Colleges Ambulance Liaison Committee
ILHCO	International Liaison Committee on Resuscitation
MeSH	Medical Subject Headings
MRC	Medical Research Council
mRS	modified Rankin Scale
NHS	National Health Service
NICE	National institute for Health and Care Excellence
NIHR	National Institute for Health Research
OHCA	Out of hospital cardiac arrest
PIL	Participant information leaflet
QALYs	Quality adjusted life years
RCA	Resuscitation Council of Asia
RCSA	Resuscitation Council of Southern Africa
RCT	Randomised controlled trial
REC	Research ethics committee
ROLE	Recognition of Life Extinct
ROSC	Return of spontaneous circulation
SAD	Supraglottic airway device
SAE	Serious adverse event - events which result in death, are life threatening, require hospitalisation or prolongation of hospitalisation, result in persistent or significant disability or incapacity.
SMG	Study management group
SOP	Standard operating procedure
TSC	Trial steering committee
UK	United Kingdom

130

131 **1. TRIAL SUMMARY**

132

133 Cardiac arrest occurs when the heart beat and breathing stop suddenly, and is one of the most extreme medical
 134 emergencies. Health outcomes are poor; 90% of patients die at the scene or before discharge from hospital. The best
 135 initial treatment is cardiopulmonary resuscitation (CPR); a combination of rescue breathing and chest compressions.
 136 Prompt and effective CPR prevents damage to the brain and other organs, and maximises the chance that the heart will
 137 start beating again.

138

139 Ensuring a clear airway, whilst interrupting chest compressions as little as possible, is essential for survival. At the
 140 moment, we do not know the best way for NHS ambulance staff to provide rescue breathing during a cardiac arrest
 141 (out of hospital cardiac arrest: OHCA). Placing a breathing tube in the windpipe (intubation) has been considered the

142 best method. However, attempting to place the breathing tube can cause significant complications as well as
143 interruptions in chest compressions (thus reducing delivery of blood and oxygen to the brain and heart).

144

145 National recommendations suggest using a newer method: insertion of a supraglottic airway device (SAD); a tube that
146 sits on top of the voice box. SADs are already used during routine anaesthesia in hospital; in emergency care, they are
147 quicker to insert and cause less interruption to chest compressions. However, a SAD does not stay in place as securely
148 as a breathing tube and, if a patient vomits, a SAD may not prevent stomach contents from entering their lungs.

149

150 There is real uncertainty amongst paramedics and experts in the field about the best method to ensure a clear airway
151 during the early stages of OHCA. We therefore propose to undertake a large research study to determine whether
152 intubation or the best available SAD (called the i-gel) gives the best chance of recovery following OHCA. The study
153 will be a randomised controlled trial (RCT) in four English NHS ambulance services. It will recruit adult OHCA
154 patients who have had a cardiac arrest that is not due to injury. Paramedics who agree to take part will be divided into
155 two groups and given structured education on CPR and rescue breathing. One group will be required to use the i-gel,
156 and the other intubation, as the first method of rescue breathing in all cases of OHCA that they attend during the study.

157

158 We will follow-up the patients in hospital, and 3 and 6 months later, to find out the quality of life of survivors and the
159 NHS resources used during their hospital stay and subsequently. We have recently completed a highly successful
160 preliminary study which has shown that this research is possible. We enrolled more than 600 OHCA patients, and
161 showed that paramedics could deliver the trial as planned, obtaining all the necessary information. We also tested two
162 different SADs, and identified the best-performing device (the i-gel) for use in this study.

163

164 The research team comprises experienced clinicians in pre-hospital, emergency and critical care, as well as expertise in
165 the development and dissemination of international resuscitation guidelines. This clinical expertise is complimented by
166 the research expertise of an established Clinical Trials Unit, the UKCRC registered Clinical Trials and Evaluation Unit
167 (CTEU) and a Health Economics Research Centre, including experts in study methods, statistics, health economics and
168 outcome assessment. The research group has strong patient and public involvement, and good links with ambulance
169 services and experts in the field within the UK and internationally. The results from this study (AIRWAYS-2) will
170 shape future OHCA guidelines and will yield real benefits to future OHCA patients in the UK and throughout the
171 world.

172

173 2. BACKGROUND

174

175 The UK has the highest reported incidence of OHCA in Europe, at 123 cases per 100,000 population per annum [1].
176 Despite recent improvements, survival rates remain poor with estimates of between 5% and 25% surviving to hospital
177 discharge internationally, and approximately 7%-9% in the UK [2-5]. Around 6% of all intensive care bed days are
178 occupied by patients who have suffered a cardiac arrest[6], and the average intensive care length of stay for this patient
179 group is steadily increasing with a current mean in excess of 5 days .

180

181 During a cardiac arrest, the brain is exposed to a variable period of hypoxaemia and ischaemia, which may result in
182 death or survival with cognitive deficits [7]. Six months after OHCA, cognitive deficits can still be detected in up to
183 half of all survivors [8]. Hypoxic-ischaemic brain injury also has an impact on other important aspects of life.
184 Survivors report symptoms of depression, dependency on others for daily functioning and a lower quality of life [9,
185 10]. Optimal CPR is one of the key factors associated with avoiding or minimising neurological impairment in the
186 survivors of OHCA, and early effective airway management is fundamental to this. Effective ventilation maintains
187 blood oxygenation, thereby reducing hypoxaemia and reducing the risk of brain damage [11, 12], and is associated
188 with both return of spontaneous circulation (ROSC) and neurological recovery following cardiac arrest[11]. This
189 increases the number of survivors and the quality of survival, with decreased dependency on acute and long-term care.
190 Importantly, however, efforts to secure effective ventilation should not prejudice the continuous chest compressions
191 that support the circulation and that are also essential for long-term survival.

192

193 Effective CPR with airway management improves survival and health related quality of life [13, 14]. The first few
194 minutes of CPR are critical; early ROSC is associated with better long-term neurological outcome[15, 16]. Traditional
195 teaching suggests that tracheal intubation (intubation) is the best way to manage the airway during OHCA [17].
196 However, this assumption has never been well tested [14], and pre-hospital intubation attempts by paramedics are
197 associated with important complications: interruptions in chest compressions, unrecognised oesophageal intubation,
198 compromised oxygenation and delays in accessing definitive care [18, 19].

199

200 Supraglottic airway devices (SADs) are an alternative to intubation. They are faster and easier to place and may reduce
201 the complications described above [20]. SADs are used safely, effectively and frequently in hospital procedures [21-
202 23]. They are now widespread in NHS ambulance services; in 2011/12 the London Ambulance Service reported 1,439
203 successful OHCA intubations, compared to 1,570 successful SAD placements[5]. Equipose between the two
204 techniques has led to recent calls for a large RCT of the two approaches [24, 25], which we propose to undertake.

205

206 **2.1 Existing Evidence**

207

208 Clinical trials registers and the databases CINAHL, Cochrane, EMBASE, Medline were searched using relevant
209 Medical Subject Heading (MeSH) terms. The only relevant research identified was our own feasibility study, which
210 was undertaken to prepare for and inform this study. In this feasibility study we completed 12 months of data
211 collection in a single NHS ambulance service, and recruitment of both paramedics (184) and patients (615) exceeded
212 our pre-determined targets.

213

214 Complete data sets were collected for >95% of patients enrolled in the trial, with overall protocol adherence in excess
215 of 90%. As expected, the relatively small sample size meant that there were no statistically significant differences
216 between study groups in the proportion of patients transported to hospital, with ROSC, surviving to hospital discharge
217 or surviving to 90 days. However, we have demonstrated that our proposed trial design is feasible, and have gained
218 important insights that have informed the design of this trial. We also have a data set on over 600 OHCA patients with
219 comprehensive follow-up and cost effectiveness data.

220

221 Work to define a core outcome data set for OHCA, using Core Outcome Measures in Effectiveness Trials (COMET)
222 methodology (see <http://www.comet-initiative.org/>), is ongoing but is not expected to report for several years; in the
223 meantime, survival, residual disability, quality of life, process measures and cost effectiveness are the most important
224 outcomes on which to focus.

225

226 **2.2 Relevance to the NHS / health policy**

227

228 Evidence-based interventions to improve OHCA survival are required urgently, but survival alone is insufficient to
229 describe the full benefits of any improvements in care. Functional status and quality of life following OHCA are
230 recognised as key outcome measures for resuscitation success [66,67].Therefore research to improve survival, and the
231 quality of that survival, remains highly relevant and important to the needs of the NHS, to patients, and to the public.

232

233 This study has the potential to improve the quality of CPR, survival rates from OHCA and the quality of that survival;
234 with reduced length of stay, enhanced quality of life and reduced use of health and social care resources. We anticipate
235 potential gains for individual patients, the wider NHS and society as a whole.

236

237 This study is likely to lead to rapid and important changes in the treatment protocols recommended by the International
238 Liaison Committee on Resuscitation (ILCOR). This organisation was formed in 1992 to provide an opportunity for the
239 major groups engaged in resuscitation worldwide to work together on CPR and emergency cardiovascular care
240 protocols. ILCOR is composed of the American Heart Association (AHA), the European Resuscitation Council (ERC),
241 the Heart and Stroke Foundation of Canada (HSFC), the Australian and New Zealand Committee on Resuscitation, the
242 Resuscitation Council of Southern Africa (RCSA), the Resuscitation Council of Asia (RCA) and the Inter American

243 Heart Foundation (IAHF). As a result it has truly international reach, and its guidelines are almost universally accepted
244 as being the most up to date and effective in the field.

245

246 **3. AIMS AND OBJECTIVES**

247

248 **Aim:**

249 To determine whether the i-gel, a second-generation SAD, is superior to tracheal intubation in non-traumatic OHCA in
250 adults, in terms of both clinical and cost effectiveness.

251

252 **Objectives:**

253 1. To estimate the difference in the primary outcome of modified Rankin Scale (mRS) at hospital discharge (or 30 days
254 post OHCA) between groups of patients managed by paramedics randomised to use either the i-gel or intubation as
255 their initial airway management strategy following OHCA.

256 2. To estimate differences in secondary outcome measures relating to airway management, hospital stay and recovery
257 at 3 and 6 months (see section 4.6.2) between groups of patients managed by paramedics randomised to use either the
258 i-gel or intubation.

259 3. To estimate the comparative cost effectiveness of the i-gel and intubation, including estimating major in hospital
260 resources and subsequent costs (length of stay, days of intensive and high dependency care, etc.) in each group.

261 **4. PLAN OF INVESTIGATION**


262

263 **4.1 Trial schema**

264

265 **Figure 1: Trial schema**

266



267

268

269 **4.2 Trial design**

270

271 This is a parallel two-group multi-centre cluster randomised controlled trial (RCT) and accompanying cost-
 272 effectiveness analysis to identify the best approach to initial airway management during OHCA.

273 Randomisation by patient is impractical; we will therefore randomise by paramedic.

274

275 Paramedics will be recruited from four NHS ambulance services with favourable characteristics.

276

277 The NHS ambulance services are:

278

- 279 • South Western Ambulance Service NHS Foundation Trust (SWAST)
- 280 • East of England Ambulance Service NHS Trust
- 281 • East Midlands Ambulance Service NHS Trust
- 282 • Yorkshire Ambulance Service NHS Trust

283

284 The College of Paramedics is also fully supportive of the study.
285 Hospitals receiving OHCA patients from these ambulance services will also be taking part.

286

287 **4.3 Key design features to minimise bias**

288

289 **4.3.1 Selection bias/allocation bias (systematic differences between baseline characteristics of the groups that** 290 **are compared)**

291

292 This type of bias is usually ruled out by concealed randomisation in a trial that randomises individual patients. This is
293 not necessarily the situation with a cluster-randomised trial because inclusion of only a small number of clusters can
294 cause chance imbalances (not bias *per se*) between the groups. Since AIRWAYS-2 will recruit about 1300 paramedics
295 chance imbalances will not be a problem.
296

297 Even with concealed allocation of clusters (paramedics), bias can arise from recruitment of a different proportion of
298 eligible individuals among paramedics allocated to different airway management strategies. Moreover, even if these
299 proportions do not differ overall, differential recruitment of eligible individuals among paramedics may happen, with
300 paramedics assigned to different airway management strategies recruiting different kinds of patients (but the same
301 overall proportion). In this trial, we will avoid this bias by using a combination of methods to identify all eligible
302 patients, including direct notifications by ambulance clinicians and review of routine ambulance service data to ensure
303 >99% of the eligible patients are included (see section 5.6.1)

304

305 Bias could also be introduced by applying inclusion criteria in a biased manner, i.e. including >99% of eligible patients
306 will not be sufficient if paramedics in different groups consider different patients to be eligible. The most obvious
307 source of such bias is the application of a differential threshold for resuscitation by paramedics assigned to different
308 airway management strategies, since they will not be blinded. We will use several strategies to prevent this bias from
309 occurring, to detect it if it happens, and to correct it if necessary (see sections 4.4.2 and 5.3.7 for details).

310

311 **4.3.2 Performance bias (systematic differences between groups in the care that is provided, or in exposure to** 312 **factors other than the interventions of interest).**

313

314 This bias will be minimised by:

315

- 316 • defining the intervention and comparator, as well as standard protocols for other procedures undertaken
317 during the trial (see sections 4.5 and 5.11);
- 318 • blinding staff beyond ED (section 5.2.2) to method of initial airway management (see section 5.2.2) and
319 assessing the success of blinding (see section 5.2.2);
- 320 • monitoring adherence to the protocol (see section 7.1 and 7.2).
321

322 **4.3.3 Detection bias (systematic differences between groups in how outcomes are determined)**

323

324 This bias will be minimised by:

325

- 326 • using an objective primary outcome measure (modified Rankin Scale, see section 5.6);
- 327 • blinding individuals assessing outcomes (see section 5.2.2).
328

329 **4.3.4 Attrition bias (systematic differences in the availability of outcome data between groups)**

330

331 This bias will be minimised by:

332

- 333 • obtaining almost complete follow-up. About 90% of patients will not survive to hospital discharge. We
334 expect to be able to account for all other patients who consent to follow-up from the time of discharge up to
335 six months
336

337 **4.3.5 Reporting bias**

338

- 339 • This type of bias will be minimised by having pre-specified outcomes (see section 4.6) and a pre-specified
340 analysis plan (see section 6).
341

342 **4.4 Trial population**

343

344 Adults who have suffered an OHCA that is not due to trauma. This group comprises the large majority of OHCA
345 patients.
346

347 **4.4.1 Inclusion and exclusion criteria for paramedics**

348

349 **Paramedic Inclusion Criteria**

350

- 351 • Employed or soon to be employed by one of the four participating ambulance trusts in general operational
352 duties, and could therefore be despatched to attend an OHCA as the first or second paramedic to arrive at the
353 patient's side.
354 • Qualified to practice tracheal intubation in their current clinical role
355

356 **Paramedic Exclusion criteria**

357

- 358 • Paramedics working in non-clinical and managerial roles not routinely* attending OHCA
359

360 *Routinely is defined as usually attending at least 2 OHCA patients where resuscitation is attempted each year. This
361 however will not be a 'hard' exclusion criterion.
362

363 **4.4.2 Inclusion and exclusion criteria for patients:**

364

365 **Patient Inclusion Criteria**

366

- 367 • Patient known or believed to be 18 years of age or older
368 • Patient has had a non-traumatic cardiac arrest outside hospital
369 • Patient must be attended by a paramedic who is participating in the trial and is either the 1st or 2nd paramedic
370 to arrive at the patient's side.*1
371 • Resuscitation is commenced or continued by ambulance staff or responder*2
372

373 *1. The participating paramedic will manage the patient's airway, according to their allocation. If both the 1st and 2nd
374 paramedic are participating in the trial, the patient's airway will be managed according to the allocation of the 1st
375 paramedic to arrive at the patient's side (usually designated as the "attendant" within the ambulance service).
376

377 If the 1st paramedic to arrive is not an AIRWAYS-2 paramedic, but the 2nd paramedic is, the patient will be enrolled
378 in the study unless an advanced airway intervention has already occurred (advanced airway intervention is defined as
379 either a SAD or tracheal tube being present in the patient's mouth) at the point that the second paramedic arrives at the
380 patient's side.

381

382 If a 3rd or subsequent paramedic arrives at the patient's side, and the first two paramedics are not participating in the
383 trial but the 3rd or subsequent paramedic is participating, the patient will be excluded (such an exclusion may need to
384 be determined retrospectively).

385

386 *2 Circumstances in which resuscitation should and should not be attempted are described in national guidelines. The
387 Joint Royal Colleges Ambulance Liaison Committee (JRCALC) Recognition of Life Extinct (ROLE) criteria are
388 currently used by all ambulance trusts to determine when a resuscitation attempt is inappropriate, and these criteria will
389 be applied in this trial. These criteria are objectively defined, but the frequency of attempted resuscitation in both
390 groups will be regularly examined by the DMSC to identify any bias in the commencement of resuscitation attempts.

391

392 **Patient Exclusion criteria**

393

- 394 • Patient detained by Her Majesty's Prison Service
- 395 • Previously recruited to the trial (determined retrospectively)
- 396 • Resuscitation considered inappropriate (see below)
- 397 • Advanced airway management inserted by another HCPC registered paramedic, doctor or nurse already in
398 place when AIRWAYS-2 paramedic arrives at patient's side (when the first paramedic to arrive is not
399 participating in AIRWAYS-2)
- 400 • Known to already be enrolled in another pre-hospital randomised trial
- 401 • Mouth opening <2 cm

402

403 This last exclusion has been applied because SADs are not designed for use in patients with significantly reduced
404 mouth opening. There is a risk of post-randomisation bias being introduced by this exclusion criteria, but in our
405 feasibility study only 2/711 patients (0.3%) were excluded on these grounds. We will monitor this exclusion, under the
406 guidance of the DMSC, and should the exclusion rate exceed 1% we will take action to address this through enhanced
407 training and supervision.

408

409 Standardised guidelines, based on those produced by JRCALC, will be applied to determine patients for whom a
410 resuscitation attempt is inappropriate. This is the case when there is no chance of survival, the resuscitation attempt
411 would be futile and distressing for relatives, friends and healthcare personnel and where time and resources would be
412 wasted undertaking such measures. When any one or more of the following conditions exist, resuscitation and
413 enrolment in the trial will not take place.

414

- 415 1. massive cranial and cerebral destruction
- 416 2. hemicorporectomy
- 417 3. massive truncal injury incompatible with life (including decapitation)
- 418 4. decomposition/putrefaction
- 419 5. incineration
- 420 6. hypostasis
- 421 7. rigor mortis
- 422 8. A valid do not attempt resuscitation order or an Advanced Directive (Living Will) that states the wish of the
423 patient not to undergo attempted resuscitation
- 424 9. When the patient's death is expected due to terminal illness
- 425 10. Efforts would be futile, as defined by the combination of **all three** of the following being present
- 426 (a) More than 15 minutes since the onset of collapse
- 427 (b) no bystander CPR prior to arrival of the ambulance
- 428 (c) asystole (flat line) for >30 seconds on the ECG monitor screen. Exceptions are drowning, drug
429 overdose/poisoning
- 430 11. Submersion of adults for longer than 1 hour

431

432 Patients will also be excluded from the study if an immediate family member, relative or close friend that is present at
433 the scene of the cardiac arrest indicates to the participating paramedic at the start of the resuscitation attempt that the
434 person has previously expressed an opinion that they would not wish to take part in the AIRWAYS-2 trial.
435

436 **4.5 Trial interventions** 437

438 **4.5.1 Control group** 439

440 The current standard care pathway is tracheal intubation: the placement of a cuffed tube in the patient's trachea
441 (windpipe) to provide oxygen to the lungs and remove carbon dioxide. Tracheal intubation is considered the “gold
442 standard” of airway management, and is used universally in comatose survivors of cardiac arrest following their
443 admission to hospital.
444

445 **4.5.2 Intervention group** 446

447 The intervention being studied is the insertion of an i-gel, a second-generation SAD, as an alternative to tracheal
448 intubation.
449

450 First introduced in the 1980s, SADs have been improved recently to reduce the risk of vomit entering the lungs and to
451 enhance the airway seal. SADs have proved safe and effective during hospital procedures, and are now used more
452 often than tracheal intubation in United Kingdom operating theatres [15]. Over the past decade use of SADs has also
453 become widespread in NHS ambulance trusts. There is however substantial equipoise between the two techniques.
454 This fact enables the proposed trial to proceed ethically, and also supports its practical delivery in UK ambulance
455 Trusts.
456

457 Because of its speed and ease of insertion, and the fact that it does not require a cuff to be inflated, the i-gel has
458 emerged as the preferred SAD for use during OHCA in Europe [26, 27]. We will use the most recent version of this
459 device: the ‘i-gel Pack’.

460 461 **4.5.3 Aspects of management common to both groups:** 462

463 For both the control and intervention groups a standardised algorithm will be used to guide further actions should the
464 initial approach to airway management prove unsuccessful. Algorithms already exist in the different ambulance trusts,
465 but these will need to be adapted to provide a standardised one which can be used consistently across the 4 ambulance
466 regions. Participating paramedics will be trained in this algorithm before recruitment commences, with a refresher at
467 the mid-point of patient enrolment. The use of such an algorithm reflects routine practice, in that paramedics will
468 usually follow a specified protocol or “airway ladder” when managing the airway during OHCA. This approach will
469 standardise care in each trial arm, and all other elements of the care pathway will be identical.
470

471 Care will proceed as normal for OHCA patients enrolled in the trial, aside from the initial airway management. All
472 other interventions will proceed according to standard resuscitation guidelines that are disseminated widely in the
473 United Kingdom and internationally.
474

475 Patients who die at the scene will be managed in accordance with nationally disseminated ambulance service protocols
476 (e.g. recognition of life extinct, or confirmation of death). The remaining survivors will be transported to hospital, with
477 approximately half of these admitted to an intensive care unit (ICU). These patients will be treated using standard post-
478 OHCA care pathways.
479

480 **4.6 Primary and secondary outcomes**

481

482 **4.6.1 Primary outcome**

483

484 The primary outcome will be the modified Rankin scale (mRS) score measured at hospital discharge. However if the
485 patient remains in hospital for more than 30 days after the OHCA, the primary outcome (mRS) will be assessed at the
486 30 day time point instead of at discharge. The mRS which incorporates survival to discharge is widely used in OHCA
487 research[28, 29]. mRS is usually presented dichotomously as good recovery (0-3) or poor recovery/death (4-6).

488

489 All enrolled patients are eligible. We will collect survival data and mRS at hospital discharge with the prior
490 permission of the Health Research Authority Confidentiality Advisory Group (CAG), thereby ensuring close to 100%
491 data ascertainment.

492

493 For patients that survive to hospital discharge (or are still inpatients 30 days after their OHCA) the mRS will be
494 determined by a research nurse who will assess the patient using a simple flow chart that has been previously used to
495 assess patients who have had a cardiac arrest[30]. Any patient who does not survive to discharge will automatically be
496 assigned a score of six (dead) .

497

498 **4.6.2 Secondary outcomes**

499

500 We will seek consent from survivors (or a consultee according to the requirements of the Mental Capacity Act 2005 if
501 the patient lacks capacity) to collect additional data at hospital discharge and 3 and 6 months after OHCA (depending
502 which consent option the participant chooses-see section 9.7.1). We have chosen a 6-month final follow-up because,
503 whilst there are very few additional deaths between 3 and 6 months, quality of life and functional independence in
504 activities of daily living continue to improve during this time [31].

505

506 *All enrolled patients*

- 507 1. Initial ventilation success, defined as visible chest rise.
- 508 2. Regurgitation/aspiration.
- 509 3. Loss of a previously established airway.
- 510 4. Actual sequence of airway interventions delivered.
- 511 5. Chest compression fraction (one ambulance region only, see below).
- 512 6. Return of spontaneous circulation (ROSC).
- 513 7. Airway management in place when ROSC was achieved or the resuscitation was discontinued.
- 514 8. Economic data regarding expenditure and further healthcare contacts.

515

516 *Patients who survive to admission to hospital (estimated 20% of enrolled patients)*

- 517 9. Length of intensive care stay.
- 518 10. Length of hospital stay.

519

520 *Patients who survive to hospital discharge (estimated 9% of enrolled patients)*

- 521 11. Quality of life (using the EQ-5D) at hospital discharge

522

523 *Patients who survive beyond hospital discharge*

- 524 12. Date of death (if applicable)
- 525 13. Modified Rankin scale at 3 and 6 months following OHCA
- 526 14. Quality of life (using the EQ-5D) at 3 and 6 months following OHCA.

527

528 Good quality, continuous CPR is associated with increased survival and improved neurological outcomes following
529 cardiac arrest [24, 32], and the concept of compression fraction has been developed as a standardised way of
530 measuring and expressing this [33]. The compression fraction is defined as the proportion (or percentage) of
531 resuscitation time without spontaneous circulation during which chest compressions are administered: the higher the
532 compression fraction the better the quality of CPR, and the more likely the patient is to survive [34]. Comparing the
533 compression fraction between the two randomisation arms may help to explain the study findings. Measuring and
534 reporting compression fraction allows heterogeneity between trials to be more consistently described. A suggested
535 mechanism by which SADs may improve outcome from OHCA is a reduction in interruptions to CPR (with an
536 accompanying increase in compression fraction)

537

538 Compression fraction is not routinely measured during OHCA in England, but is technically possible [35].

539 Measurement of compression fraction requires the use of modified defibrillator-monitors, we do not believe it is
540 practical, or affordable, to measure this in all enrolled patients. Instead, we will implement technology that allows
541 compression fraction to be routinely measured during CPR in a sub-set of enrolled patients (for example in one of the
542 four participating ambulance trusts) and collect these data alongside the other outcome measures. This will enable
543 compression fraction to be compared in a subset of the two trial arms, and will also benefit future studies by
544 introducing and evaluating the technology required to routinely measure compression fraction during OHCA.

545

546 **4.7 Sample size calculation**

547

548 In our feasibility study 9% of recruited patients survived to hospital discharge, and this is the current rate of overall
549 survival to discharge reported by English ambulance trusts (see:

550 <http://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/ambqi-2012-13/>). A 2%
551 improvement in the proportion of patients achieving a good neurological outcome (mRS score of 0-3) would be
552 clinically significant, and similar to the 2.4% difference in survival to discharge between tracheal intubation and SADs
553 reported in a recently published retrospective analysis [18].

554

555 To identify a difference of 2% (8% vs. 10%, i.e. centred on 9%) requires 4,400 patients per group (at the 5% level for
556 statistical significance and 90% power). However, each OHCA is not an independent observation, as the patients are
557 nested within a limited number of attending paramedics. Using data from our feasibility study of 171 paramedics
558 attending 597 OHCA, we estimated the intraclass correlation (ICC) to be <0.001. However, when estimating the
559 sample size we have assumed a conservative estimate for the ICC of 0.005. We estimate that 1,300 paramedics will
560 participate; this gives an adjusted sample size of 4,535 patients per group (9,070 in total). In our feasibility study the
561 mean number of patients enrolled per participating paramedic was 3.6 per year, which translates to 7 patients per
562 paramedic over our planned two-year recruitment period ($7 \times 1,300 = 9,100$).

563

564 In the feasibility study within the Great Western Ambulance Service 171 from 535 eligible paramedics (32%) agreed
565 to take part. The total pool of eligible paramedics across the four ambulance trusts participating in AIRWAYS-2 is
566 more than 4,300, and 32% of this total provides more than 1,350 participating paramedics.

567

568 **5. TRIAL METHODS**

569

570 **5.1 Description of randomisation**

571

572 OHCA is an extreme medical emergency requiring immediate attendance and action by skilled paramedic staff in a
573 wide range of unpredictable environments. For this reason, the procedures that would be required to achieve
574 randomisation by patient (contacting a remote server or telephone line, or even opening a sealed opaque envelope) are
575 impracticable at the point when an eligible patient is identified. Indeed, almost all similar research studies have been
576 cluster-randomised, often at the level of ambulance stations [36-38]. This in turn has led to concerns regarding
577 compliance and bias, and for this reason our team has investigated the principle of randomisation by paramedic.

578

579 Randomisation of paramedics has the advantage of producing a large number of relatively small clusters (each
580 paramedic is a cluster), which more closely approaches individual patient randomisation, and also supports effective
581 stratification so that the characteristics of randomisation groups are more likely to be similar. In our feasibility study
582 we used this approach successfully. Randomisation will be stratified by ambulance trust, clinical experience and the
583 location of the paramedic's base ambulance station. This will ensure balance of clinical expertise of the attending
584 paramedic, and ambulance response times relating to an urban or rural environment, across the two groups, thereby
585 increasing the likelihood that baseline characteristics of patients will be balanced.

586

587 Paramedics who consent to take part in the study will be randomised to the i-gel or the intubation after they have
588 consented but before they start trial group specific training. Randomisation will be performed using an in-house
589 computer based system with secure allocation concealment that cannot be changed once allocated, and will allocate the
590 paramedics in a 1:1 ratio to the two groups.

591

592 Randomisation will be carried out by a member of the CTEU Bristol, or appropriately trained member of the research
593 team.

594

595 Code breaking will not be necessary since paramedics will be aware of their allocation, and whilst the intervention is in
596 progress the allocated treatment will be apparent. Furthermore, once the intervention has been completed subsequent
597 in-hospital treatment is not influenced by study allocation.

598

599 **5.2 Procedures to minimise bias**

600

601 **5.2.1 Selection/allocation bias**

602

603 First, established objectively defined criteria will be used by participating paramedics to determine whether a
604 resuscitation attempt is appropriate, and hence whether the patient is eligible (see standardised resuscitation guidelines,
605 section 4.4.2).

606

607 Second, we will institute a programme of regular monitoring by analysing the proportion of cardiac arrests recruited, to
608 detect any imbalances that may be caused by different thresholds for resuscitation. We will also monitor the presenting
609 rhythm, proportion of witnessed and un-witnessed arrests, presence of bystander CPR and time from 999 call to crew
610 arrival.

611

612 If we suspect that a different threshold for resuscitation is being applied by one or more paramedics participating in the
613 trial, the first step will be to identify the personnel involved and ensure that their training in the trial procedures is up to
614 date, and reinforce the essential messages about the rationale for the trial. The trial team will include a local research
615 paramedic in each of the 4 ambulance regions, this person will develop a close working relationships with the
616 participating paramedics, and will be ideally placed to undertake this role.

617

618 **5.2.2 Blinding**

619

620 Because of the nature of the intervention, ambulance clinicians cannot be blinded, and will be aware of treatment
621 allocations, with an attendant risk of performance bias. However control room personnel will be blinded to the
622 allocation of paramedics, and follow established protocols when allocating resources to a possible cardiac arrest. This
623 will ensure that there is no bias in despatch.

624

625 Patients will be unaware of their treatment allocation at the time of the intervention, and this is likely to be maintained
626 throughout the trial. Research staff assessing outcomes at hospital discharge and at the 3 and 6 month follow-up will

627 also be blinded to treatment group and this will be formally assessed during the study. Blinding of participants and
628 clinical personnel will minimise performance bias.
629

630 Unfortunately emergency department staff cannot be blinded to which treatment arm (intubation or i-gel) the patient
631 was allocated to, as the patient will arrive in the ED with either intubation tube or i-Gel in situ, with the difference
632 between them being visually apparent. We will however be able to blind clinical staff, whom care for the patient
633 beyond ED to the method of initial airway management used. Therefore the care of the patient beyond the emergency
634 department will not be affected by knowledge of the intervention used.
635

636 **5.3 Research procedures**

637

638 **5.3.1 Training of Paramedics**

639

640 Standardised training materials (including learning objectives and lesson plans) have been developed to support
641 training in research procedures and the allocated airway management technique for both the control and intervention
642 groups. These will be administered to all participating paramedics before enrolment commences, with a research
643 refresher halfway through the recruitment period (at 12 months). Concerns have been raised that after two years using
644 one method of airway management participating paramedics risk becoming de-skilled in alternative approaches, and
645 therefore to support effective paramedic recruitment and retention we will offer additional “exit” training to all
646 participating paramedics to update their airway skills once patient enrolment has been completed.
647

648 Alongside this training we will institute a range of measures to encourage and promote ongoing participation and
649 momentum amongst paramedics. These will be adapted from previously successful research in ambulance trusts and
650 will include a study newsletter, regular publicity and updates, marking of key milestones and formal recognition of
651 success. We have also secured a formal endorsement from the College of Paramedics in supporting the recruitment and
652 retention of participating paramedics, and disseminating the study results.
653

654 The first training session will consist of generic training on resuscitation and the study procedures, data collection and
655 we will explain the trial, equipoise and the need to follow protocol. We will then invite paramedics to sign a consent
656 form or leave training, without prejudice. We will randomise paramedics who have consented to take part in the trial to
657 one of the two groups (i-gel or intubation). The paramedics will then be divided into two groups according to their
658 allocation, and complete technical training specific to each trial group. We will then answer any questions that have
659 arisen and complete the training session.
660

661 **5.3.2 Tracheal Intubation**

662

663 Tracheal intubation requires the use of a laryngoscope to see the patient’s larynx, followed by the placement of a tube
664 at the correct level in the trachea, and is usually undertaken only by doctors and paramedics. The ease with which
665 tracheal intubation can be accomplished varies from patient to patient, and it requires training to develop this skill,
666 followed by ongoing practice to ensure that the skill is maintained. Sometimes tracheal intubation cannot be achieved,
667 or the tracheal tube may be placed in the patient’s oesophagus by mistake. If the latter circumstance goes unrecognised
668 the patient is unlikely to receive any oxygen during their cardiac arrest and it is well recognised that, even if a tracheal
669 tube is correctly placed, the technical demands of achieving intubation can lead to long pauses in the chest
670 compressions that are vital to resuscitation success [18]. To ensure that the standard care pathway is optimised, and the
671 chance of successful tracheal intubation maximised, all participating paramedics will be equipped with an intubating
672 bougie and end-tidal carbon dioxide monitoring.
673

674 **5.3.3 Placement of i-gel**

675

676 Placement of an i-gel is much simpler than tracheal intubation, and does not require the use of a laryngoscope. The i-
677 gel device is simply inserted, in the correct orientation, into the patient’s mouth and pharynx, where it usually provides
678 a direct channel from the mouth to the opening of the trachea. Sometimes however the i-gel will not form a satisfactory

679 seal, leading to leakage and a failure to ventilate the lungs. There is also a risk that gastric contents (vomit) will
680 regurgitate and enter the lungs (this is prevented by the cuff on a tracheal tube), or that the i-gel will dislodge if the
681 patient is rolled or moved and so the training of the paramedics in the correct placement of the I-gel is very important.

682

683 **5.3.4 Use of study devices**

684

685 The study devices are only to be used by paramedics for patients fulfilling the eligibility criteria for the trial. The
686 devices are supplied and approved for the trial only, and paramedics have access to standard airway equipment to use
687 in other situations.

688

689 **5.3.5 Measurements of compression fraction:**

690

691 Previously compression fraction has been measured by fitting general packet radio service modems to compatible
692 Lifepak 15™ defibrillators used by paramedics, and automatically transmitting a download of CPR data after each
693 OHCA (to which paramedics are blinded) for subsequent remote analysis by a research team using freely available
694 software [35]. We intend to use a similar approach in this study, tailored to the defibrillators and supporting technology
695 available.

696

697 **5.4 Duration of treatment period**

698

699 The duration of treatment will be the pre-hospital phase of an enrolled patient's cardiac arrest; likely to be between 15
700 and 90 minutes.

701

702 **5.5 Definition of end of trial**

703

704 For individual patients the trial will end after the final follow-up, six months after the index cardiac arrest (for patients
705 consented under option A or B) or immediately after approach for consent for patients who select option C or do not
706 respond when approached to consent. The trial as a whole will end once all participants have completed the follow-up
707 phase or have been lost to follow-up. This will be six months after the last patient is enrolled in the study.

708

709 **5.6 Data collection**

710

711 Data collection will include the following elements:

712

- 713 a) A log of all paramedics approached and a record of those who consent to take part in the study
714
- 715 b) A log of all patients that have an OHCA who are attended by a paramedic within one of the four participating
716 ambulance trusts.
717
- 718 c) A log of those attended by an AIRWAYS-2 paramedic (together with details of whether resuscitation was
719 attempted)
720
- 721 d) A log of all OHCA patients attended by an AIRWAYS-2 paramedic (where resuscitation is attempted)
722 assessed against the eligibility criteria and, if ineligible, reasons for ineligibility.
723
- 724 e) A screening log of all OHCA patients enrolled in the study who survive to ICU/ cardiac care unit (CCU)
725 discharge
726

- 727 f) Survivors who are approached for consent (including the date when they are given the patient participant
728 information leaflet (PIL)) and outcome of the consent process.
729
- 730 g) For those who consent to active follow-up, responses to quality of life and mRS questionnaires collected at
731 time of consent and at follow-up at 3 and 6 months.
732
- 733 h) Key data items from routine data sources for survivors who consent and for those who die prior to discharge
734 from ICU/CCU.
735
- 736 i) Demographic characteristics of surviving OHCA patients who do not consent and withdraw from the study.
737 These data will be requested without any patient identifiers in order to maintain anonymity. The following
738 information will be sought:
739 -NHS number
740 -date of birth
741 -sex
742 -data to characterise socio-economic status (partial postcode)
743

744 Data collection will occur during the out of hospital treatment phase, during the inpatient phase of care, at hospital
745 discharge and at 3 and 6 months (\pm 4 weeks) after the index OHCA (Table 1).
746

747 Training in data collection and case report form (CRF) completion will be provided by the research nurse in each
748 region, coordinated and supported by the central study team. A fixed fee per patient has been included in the study
749 research costs to support the collection of study-specific outcome data.
750

751 **Table 1 Summary of data items and data collection points**

<i>Data item</i>	Out of hospital treatment phase <i>(data collection by paramedics)</i>	Hospital discharge <i>(data collection by hospital staff)</i>	3 month post OHCA	6 month post OHCA
Eligibility	✓			
Airway management	✓			
Demography	✓	✓		
Survival	✓	✓	✓	✓
Patient movements	✓	✓		
Approached for consent		✓		
Modified Rankin Scale		✓	✓	✓
EQ-5D		✓	✓	✓
Economic data	✓	✓	✓	✓
Serious Adverse events	✓	✓	✓	✓
Length of hospital stay/ ward movements		✓		

752

753 To minimise bias, outcome measures are defined as far as possible on the basis of objective criteria. All personnel
754 carrying out outcome assessment beyond the emergency care department care will be blinded; this will minimise
755 detection bias.

756

757 **5.6.1 Identification of patients with OHCA**

758

759 For this study we are using a model of deferred consent for survivors. All eligible patients attended by a participating
760 paramedic will be automatically enrolled in the study. Therefore, to avoid bias, it is essential to establish mechanisms
761 that will reliably identify every one of these patients. We will achieve this by identifying every OHCA (where
762 resuscitation is attempted) that occurs in the participating ambulance services throughout the study period, along with
763 the subset of patients eligible for study inclusion. Our process to achieve this is described below. It allows regular
764 review by the DMSC to identify any allocation bias, and also supports a complete intention to treat analysis.

765

766 In April 2011 the Department of Health for England introduced survival from cardiac arrest as part of the
767 Ambulance Service National Quality Indicator set. Return of spontaneous circulation and survival to hospital discharge
768 rates are reported for all patients who have resuscitation started or continued by an NHS ambulance service after an
769 OHCA [39]. For this reason all cardiac arrests are routinely identified by English ambulance services, with regular data
770 collection and return. This process is currently being strengthened through the introduction of an electronic patient
771 record and a national OHCA registry, based at the University of Warwick [40]. To ensure near-complete patient
772 identification we will use a triangulation method developed during our feasibility study. This collects data on all
773 OHCA's occurring within an ambulance service from three separate sources:

774

775 A. Direct paramedic report: participating paramedics are asked to complete a CRF immediately after each eligible
776 OHCA that they attend, and notify the coordinating research paramedic by telephone, text or e-mail.

777

778 B. Daily review of the ambulance computer aided dispatch (CAD) system, by a project research paramedic, to identify
779 all 999 calls from the previous 24 hours identified as suspected or confirmed cardiac arrest, and follow-up with the
780 relevant ambulance staff to determine whether OHCA had occurred.

781

782 C. Regular review of the OHCA data routinely collected by that ambulance trust, and reported as part of the
783 Ambulance Service National Quality Indicator set. This is usually based on the clinical record (paper or electronic)
784 routinely completed by ambulance staff after each case that they attend.

785

786 Source A will be the primary data source for the study. However, by triangulating data from all three sources it is
787 possible to reliably identify all, or nearly all, OHCA's where resuscitation is attempted during the study period. Whilst
788 it is possible for an eligible OHCA to be overlooked by this triangulation process, it would require that an arrest not be
789 reported to the research team by a participating paramedic, not be identified as an OHCA on the CAD and not be
790 picked up by the ambulance trust's routine identification and reporting system. We estimate that the chance of this
791 happening is very low, thereby ensuring an exceptionally high rate of eligible patient identification that reduces
792 selection bias to an absolute minimum.

793

794 **5.6.2 Out of hospital treatment phase (data collection by paramedics)**

795

796 After treating an eligible OHCA patient, the participating paramedic responsible for airway management will complete
797 a CRF to capture baseline and secondary outcome data. The CRF will be completed at the same time as routine
798 ambulance service paperwork: immediately after the patient has been handed over to the receiving hospital team or
799 resuscitation attempts have been discontinued at the scene. The CRF should then be returned as soon as possible
800 (preferably within 24 hours) to the coordinating research paramedic by a secure method chosen by each trust e.g. post,
801 secure fax or e-mail. Occasionally the participating paramedic will not complete the form immediately, in which case
802 they will be contacted by the research paramedic subsequently, and encouraged and supported to do so.

803

804 Even when this does not occur, relevant data can be extracted from the routine ambulance service record within 48
805 hours, allowing the patient to be followed up in order to obtain consent and collect primary and secondary outcome
806 data. Ambulance services reliably collect data regarding the individuals attending each patient and the time of staff
807 arrival: therefore for every eligible patient the attending ambulance paramedic(s), trial allocation and a range of
808 baseline data can be determined with near 100% accuracy.
809

810 **5.6.3 Hospital discharge (data collected by hospital staff)**

811

812 Once a patient has been admitted to hospital the consent and follow-up process will be coordinated by a research nurse
813 allocated to each participating ambulance service. This has been identified as a separate, hospital-based post to ensure
814 that consent and follow-up is blinded to treatment. The research nurse will usually be based in the main “heart attack
815 centre” or major receiving hospital for that region, since there is increasing evidence to support the centralisation and
816 specialisation of care for the survivors of OHCA, thereby improving outcomes [41].

817

818 Survivors of OHCA tend to be transferred to such centres. Each research nurse will receive regular lists of enrolled
819 patients who have been brought to the receiving hospitals in that ambulance service region.

820 The research nurse will coordinate the process of identification, consent and follow-up data collection with support
821 from the central team. Although the research nurse will undertake this personally where necessary, in the majority of
822 cases the consent and follow-up processes will be undertaken by existing research staff at the receiving hospitals.

823

824 **5.7 Source data**

825

826 Source data are defined as the data held in the originating ambulance and hospital information systems. For quality of
827 life data and questionnaires relating to mRS completed by telephone/ post/internet at follow up, the questionnaires
828 themselves will be the source data. The source data for health resource outcomes will mainly be extracted from
829 Hospital Episode Data. Where this is not possible, the data will be collected on the study CRF (with the source data
830 being the patient’s medical record).

831

832 **5.8 Planned recruitment rate**

833

834 Recruitment is expected to take place over a 24 month period with 9,070 patients required in total (4,535 in each of the
835 two trial groups). Recruitment will be split across the 4 ambulance trusts (section 4.2) with the number of paramedics
836 recruited in each region being proportionate to the total number of eligible paramedics employed within that region.

837

838 This projected rate of recruitment is based on information obtained in our feasibility study. We recruited from Great
839 Western Ambulance Service (GWAS), which had a pool of 535 eligible paramedics. GWAS was relatively small, and
840 has since been acquired by South Western Ambulance Service, which has a pool of >1,500 eligible paramedics. The
841 three other ambulance services that have committed to the research have a combined pool of >3,200 paramedics.
842 Therefore, the four centres have eight times the paramedics of the feasibility study.

843

844 Based on our feasibility work we are confident we can enrol 1,200 OHCA patients per year in each of four
845 participating ambulance trusts, giving >9,000 patients over two years of recruitment.

846

847 **5.9 Participant recruitment**

848

849 **5.9.1 Paramedics**

850

851 Paramedics in the 4 trusts who have provided formal letters of support for the study will be invited to participate in the
852 study through a process of informed consent (Section 9.5). The study will be well publicised in participating
853 ambulance trusts using routine communications and bulletins, supplemented by personal invitation letters, posters and
854 awareness-raising events.

855

856 **5.9.2 Patients**

857

858 For this study we are using a model of deferred consent for survivors. All eligible patients attended by a participating
859 paramedic will be automatically enrolled in the study. For details on how these patients are identified see section 5.6.1.

860

861 **5.10 Discontinuation/withdrawal of participants**

862

863 If a participant wishes to withdraw from the study after providing consent, we will continue to analyse any data already
864 collected but no further data collection will take place.

865

866 **5.11 Frequency and duration of follow up**

867

868 Follow-up will occur at 3 and 6 months (\pm 4 weeks) after OHCA. The follow up will usually be carried out by
869 telephone or as a postal or online questionnaire co-ordinated by the Bristol CTEU. If this proves to be impractical,
870 follow up may be carried out by the research nurse and may occur in hospital, but more commonly at an outpatient
871 appointment (ideally coinciding with routine clinical follow-up) or in the patient's home/usual place of residence. The
872 primary and secondary outcome measures have been selected to be versatile in this regard, and have been validated for
873 telephone administration [41-45].

874

875 **5.12 Likely rate of loss to follow-up**

876

877 In the feasibility study 7% of paramedics withdrew from the study during the 12 month data collection phase and 86 %
878 of patients discharged from hospital consented to follow up at 3 months. We would expect similar figures for this
879 study.

880

881 **5.13 Expenses**

882

883 A payment of overtime and travel expenses will be made to paramedics each time they attend one of the study training
884 sessions. The initial training session is mandatory for all paramedics who wish to take part in the study and attendance
885 at the refresher training and exit training will be strongly encouraged.

886

887 No expenses will be payable to participants because participants will not be required to make any additional visit to
888 hospital, to their GP or to any other health or welfare professional for the study.

889

890

891 **6. STATISTICAL ANALYSES**

892

893 **6.1 Plan of analysis**

894

895 The primary outcome of mRS at discharge or 30 days post OHCA (presented dichotomously as good recovery (0-3) or
896 poor recovery/death (4-6)), and other binary outcomes, will be analysed using a multilevel logistic regression model, in
897 which the data are nested within attending paramedic. Repeated mRS scores will be analysed using multilevel logistic
898 regression for repeated measures. Survival to 6 months and other time-to-event outcomes will be analysed using

AIRWAYS-2

21st December 2017

Protocol – version 6.0.

899 survival analysis methods, again allowing for clustering of patients by paramedic. Patient responses to the individual
900 EQ-5D questions will simply be described because these will be available only for survivors. Overall quality of life
901 utility scores and patient survival will be analysed jointly to assess whether the use of the i-gel supraglottic airway
902 device simultaneously improves the patient's quality of life and reduces the risk of death.

903

904 Enrolled patients who are subsequently identified as being ineligible will remain within the trial and be included in
905 analyses with the exception of a) patients who were subsequently found to have been previously enrolled in the trial; b)
906 patients who were inadvertently enrolled in the study due to being treated as a study participant by a paramedic who
907 arrives later than second at the patient's side; c) patients who are subsequently identified as being children (aged < 16
908 years); individuals aged 16 and 17 years will be included in analyses." . Analyses will be done according to the
909 principle of intention-to-treat, and reported according to the CONSORT guidelines [46, 47].
910

911 A detailed analysis plan will be prepared and agreed with the DMSC before the database is locked and any
912 comparisons between groups are investigated.

913

914 Non-adherence to allocated group will be documented. The trial will be analysed on an intention-to-treat basis, i.e.
915 outcomes will be analysed according to the treatment allocation, irrespective of future management and events, and
916 every effort will be made to include all participants treated by a study paramedic who meet the inclusion criteria.
917 Follow-up for the outcomes measures during the participant's stay in hospital and at the 3 month and 6 month window
918 should be complete for all participants that consent to taking part in the study.

919

920 **6.2 Subgroup analyses**

921

922 Two sub-group analyses are planned: the Utstein comparator group (estimated to make up about 20% of the total) vs.
923 non-comparator group, and arrest witnessed by ambulance staff (estimated to make up 6% of the total) or not. We will
924 describe the outcomes in the sub-groups and test for differences in the primary outcome between subgroups by
925 including interaction terms in the models, although we recognise that the power to detect such differences will be low
926 as the proportions in the subgroups will be unequal.

927

928 **6.3 Frequency of analyses**

929

930 The primary analysis will take place when follow-up is complete for all recruited participants. Formal interim analysis
931 is planned at the mid-point of recruitment (after 12 months), and will be presented to the DMSC. Safety data will be
932 reported together with any additional analyses the committee request. In these reports the data will be presented by
933 group but the allocation will remain masked.

934

935 **6.4 Criteria for the termination of the trial**

936

937 The trial may be terminated early on the instruction of the trial steering committee (TSC) when following
938 recommendations from the DMSC or if an interim analysis of the data from this trial or the results of another study
939 supersede the necessity for completion of this study.

940

941 The trial will also be stopped prematurely if mandated by the Research Ethics Committee (REC) or if funding for the
942 trial ceases.

943

944 The REC will be notified in writing if the trial has been concluded or terminated early.

945

946 **6.5 Economic evaluation**
947

948 For the economic evaluation we will follow established guidelines as set out by the National Institute for Health and
949 Care Excellence (NICE)[48]. The evaluation will be undertaken from an NHS and personal social services perspective.
950 A cost-utility analysis will be conducted, since the primary outcome measure for the economic evaluation will be
951 quality adjusted life years (QALYs) [49], estimated using the EuroQol EQ-5D-5L [50, 51]. These data will be
952 collected for all survivors at hospital discharge and 3 and 6 months after their OHCA. The EuroQol EQ-5D-5L will be
953 administered in person by a research nurse blinded to treatment allocation at discharge. The 3 and 6 month EQ-5D will
954 be co-ordinated by Bristol CTEU and will be administered to the patient/consultee either by telephone, or by a postal
955 or web-based questionnaire. If this proves impractical a research nurse can administer the questionnaire to the
956 patient/consultee at either an outpatient clinic appointment (timed where possible to coincide with routine clinical
957 follow-up) or by visiting the patient's home.

958
959 Given that patients will be unable to complete a baseline EQ-5D-5L questionnaire, a baseline valuation will be
960 assigned to all patients informed by the current literature. Respondents to the EQ-5D-5L will be assigned valuations
961 derived from published UK population tariffs for the EQ-5D-3L [52]and using the crosswalk value set available from
962 the EuroQol website (<http://www.euroqol.org>), or using a UK population tariff for the EQ-5D-5L if published prior to
963 the analysis of the trial. These valuations will then enable QALYs gained per patient to 6 months to be calculated.

964
965 Resource use data will be collected on the two alternative initial airway management methods delivered by
966 paramedics, resources used once in hospital such as targeted temperature management, interventions in the cardiac
967 catheter laboratory (e.g. angioplasty) and intensive care unit stay. We will also collect any resources which may be
968 related to the patient's OHCA following hospital discharge such as hospital readmissions, outpatient and Accident and
969 Emergency visits and contacts with general practice. Resource use data will either be extracted from the Hospital
970 Episode Statistics (HES) data set or be collected as part of the trial CRFs up to hospital discharge. Linkage of study
971 data to resource use data from the HES data set will be undertaken with the prior permission of the Health Research
972 Authority Confidentiality Advisory Group (CAG). This will allow us to obtain resource use data for all patients,
973 regardless of their consent status. At 3 and 6 months data will be captured using bespoke resource use questionnaires.
974 Any hospital admissions in this follow up period will also be confirmed using the HES data set. We demonstrated the
975 ability to successfully collect these economic data during our feasibility study.

976
977 A detailed preliminary study (currently pre-publication) led by one of this proposal's co-applicants (Brett) has been
978 performed on a dataset from the London Ambulance Service and Imperial College Healthcare NHS Trust, the latter of
979 which is a major de facto cardiac arrest and heart attack centre in North West London. This has allowed us to develop
980 an understanding of the likely proportions of patients surviving to the various "way-points", and to develop the CRFs
981 to comprehensively capture the resources used, and hence the costs incurred, to then perform this patient level cost
982 effectiveness analysis in accordance with NICE guidelines. Unit costs will be derived from nationally published
983 sources and Trust finances, and attached to the resource use data.

984 Missing data will be handled using multiple imputation methods[53]. We will report the cost and quality of life data
985 for each trial group and the difference between the groups, accounting for the effect of the clustering. From the average
986 costs and QALYs gained in each trial group, the incremental cost-effectiveness ratio will be derived, producing an
987 incremental cost per QALY gained of i-gel compared to intubation [54]. Given this is a cluster randomised trial,
988 statistical methods for combining costs and outcomes will need to take account of the correlation between costs and
989 outcomes at both the individual level and also at the cluster level [55, 56]. The i-gel will be considered cost-effective
990 if the incremental cost-effectiveness ratio falls below £20,000, the level below which NICE generally recommends
991 interventions to the NHS [57]. Univariate and multivariate sensitivity analyses will show what impact varying key
992 parameters in the analysis has on baseline cost-effectiveness results. Results will be expressed in terms of a cost-
993 effectiveness acceptability curve, which indicates the likelihood that the i-gel is cost-effective for different levels of
994 willingness to pay for health gain.

995
996

997 **7. TRIAL MANAGEMENT**
998

999 The trial will be managed by the Clinical Trials and Evaluation Unit (CTEU Bristol). The CTEU Bristol is
1000 an UK Clinical Research Collaboration registered Clinical Trials Unit. The CTEU Bristol will prepare all
1001 the trial documentation and data collection forms, specify the randomisation scheme, develop and maintain
1002 the study database, check data quality as the trial progresses, monitor recruitment and carry out trial
1003 analyses in collaboration with the clinical investigators.

1004

1005 **7.1 Day-to-day management**
1006

1007 The trial will be managed by a study management group (SMG), which will meet by teleconference
1008 approximately monthly. The SMG will be chaired by the chief investigator and will include all members of
1009 the named research team (see Chief Investigators & Research Team Contact Details).

1010

1011 A trial manager will be responsible for the day-to-day running of the trial, obtaining approvals, reporting to
1012 TSC, DMSC and REC, managing the budget, drafting reports and research papers. The trial manager will
1013 report to the chief investigator regularly. They will liaise closely with the other trial staff and will ensure
1014 that all individual research components are undertaken in a timely manner and within budget.

1015 They will undertake monitoring procedures at a level appropriate to a risk assessment performed by the
1016 sponsor to ensure delivery of the study in accordance with the protocol and the statutory instruments.

1017

1018 **7.2 Monitoring of sites**
1019

1020 **7.2.1 Initiation visit**
1021

1022 Before the study commences training sessions for the study research paramedics and study research nurses
1023 will be organised by CTEU Bristol. These sessions will ensure that personnel involved in the study fully
1024 understand the protocol, CRFs and the practical procedures for the study.

1025

1026 **7.2.2 Site monitoring**
1027

1028 The trial coordinating centre will carry out regular monitoring and audit of compliance with GCP and data
1029 collection procedures described in section 5.6.

1030

1031 **7.3 Trial Steering Committee and Data Monitoring and Safety Committee**
1032

1033 The TSC will meet approximately every 6 months. It will consist of an independent chair, appropriate
1034 clinical and investigator expertise and two patient representatives.

1035

1036 The DMSC meetings will be timetabled at points appropriate to reporting findings from the DMSC into the
1037 TSC meetings. One DMSC meeting will coincide with the formal mid-point review.

1038 The committee will consist of an independent statistician and two independent research-active clinicians.
1039 Patient and public involvement group meetings will be held every 4 months for the study duration.

1040

1041 **8. SAFETY REPORTING**

1042

1043 Serious and other adverse events will be recorded and reported in accordance with the International Conference for
1044 Harmonisation of Good Clinical Practice (ICH GCP) guidelines and the Sponsor’s Research Related Adverse Event
1045 Reporting Policy (see Figure 2).

1046


1047 Note: Elective surgery/interventions/treatment (e.g. planned non-cardiac surgery) during the follow-up period that was
1048 planned prior to recruitment to the trial will not be reported as an unexpected SAE.

1049

1050 **Figure 2: Serious adverse event reporting flow chart**

1051

1052



1053

1054 * These unexpected related events will also be reported to the local relevant R&D ambulance trust.

1055

1056 **8.1 Additional terms for device trials**

1057

1058 For trials of devices, additional terms are used, defined as follows:

- 1059 • Adverse Device Effect/Event (ADE): Any unfavourable or unintended response to a medical device.
- 1060 • Serious Adverse Device Effect (SADE): An ADE that has resulted in any of the consequences of a serious adverse
1061 event (SAE) or might have led to those consequences if suitable action/intervention had not been taken.
- 1062 • Incident: Any malfunction or deterioration in the characteristics and/or performance of a device, as well as any
1063 inadequacy in the labelling or instructions for use which directly, or indirectly, might lead to or might have lead to
1064 the death of a patient, or user or of other persons or to the serious deterioration in their state of health.
- 1065

1066 **8.2 Expected adverse events**

1067

1068 All of the patients in this trial will be in an immediately life-threatening situation, many will not survive, and all of
1069 those that do will be hospitalised. These situations are therefore expected, and events leading to any of them should be
1070 reported as SAE/SADEs only if their cause was clearly separate from the cardiac arrest. Events that are related to
1071 cardiac arrest and would be expected in patients undergoing attempted resuscitation (including death and
1072 hospitalisation) should not be reported.

1073

1074 **8.3 Unexpected adverse events**

1075

1076 Events should be reported as SAE/SADEs only if they: are serious AND are potentially related to trial participation i.e.
1077 may have resulted from study treatment such as use of the SAD device; AND are unexpected i.e. the event is not an
1078 expected occurrence for patients who have had a cardiac arrest.

1079

1080 Examples of events that may be SAE/SADEs are; use of an SAD causing a new injury that endangers the patient,
1081 malfunction of the device causing injury to ambulance clinicians, malfunction of the device leading to inadequate
1082 ventilation.

1083

1084 **8.4 Period for recording serious adverse events**

1085

1086 Data on adverse events will be collected start of the intervention for the duration of the participant's post-operative
1087 hospital stay and for the 6 month follow-up period.

1088

1089

1090 **9. ETHICAL CONSIDERATIONS**

1091

1092 Research in out of hospital cardiac arrest (OHCA) is challenging because it requires the recruitment of incapacitated
1093 adults without any opportunity to achieve prior consent. The nature of the condition is such that it occurs without
1094 warning, the patient is instantaneously incapacitated and immediate treatment is an absolute priority, leaving no
1095 possibility of consultation prior to resuscitation. Furthermore, because this is a trial of initial airway management, in
1096 the first minutes of OHCA, the intervention is completed within 30-60 minutes of the cardiac arrest. Therefore, by the
1097 time consent can be sought it is not possible to decline to participate. For this reason strict ethical safeguards, robust
1098 patient and public involvement and a high degree of clinical equipoise between treatment groups is essential. This
1099 study achieves all of these, and meets the requirements of the Mental Capacity Act 2005 to proceed in the absence of
1100 prior consent. Both treatment options are currently utilised as routine care in the English ambulance trusts, and there is
1101 established uncertainty as to which is the better option.

1102

1103 We are fortunate to benefit from strong patient and public involvement. In our feasibility study we used a model of
1104 deferred consent for survivors, and did not inform the relatives of those patients who do not survive the initial cardiac
1105 arrest that their loved one had been enrolled in a research study. Informing relatives that their recently deceased loved
1106 one was involved in a research study has a high risk of increasing distress and uncertainty without benefit.

1107

1108 The ethical issues in this proposal are identical to those in our feasibility study, for which we secured approval from
1109 the Cambridge Central NHS REC: this committee has specific authority to review trials of a medical device in
1110 incapacitated individuals.

1111

1112 Following the acquisition of GWAS by South Western Ambulance Service we have developed a dedicated OHCA
1113 patient and public research advisory group which has already met three times and has further endorsed and developed
1114 this approach to patient consent and relative information. This group recommends that patients be approached,
1115 informed of the study and asked to consent at the time that they are discharged from the intensive care unit, or that a
1116 close relative is approached if the patient remains incapacitated at this time. This lay group has also endorsed the
1117 routine collection of anonymised core outcome data.

1118

1119 Recruitment of paramedics raises no particular ethical issues since they are NHS staff who are able to consider the
1120 study over a period of time and give informed, written consent.

1121

1122 **9.1 Review by an NHS Research Ethics Committee (REC)**

1123

1124 Ethics review of the protocol for the trial and other trial related essential documents (e.g. PIL and consent form) will be
1125 carried out by a UK NHS REC.

1126

1127 Any amendments to these documents, after a favourable opinion from the REC has been given, will be submitted to
1128 the REC for approval prior to implementation.

1129

1130 **9.2 Review by Health Research Authority Confidentiality Advisory Group (CAG)**

1131

1132 We will seek approval from the CAG to

1133

1134 a) Collect data which will enable us to identify all patients who have been enrolled in the trial (see section
1135 5.6.1). As there is no automatic linkage between ambulance service data and hospital data, variable processes
1136 have arisen ad hoc throughout England. We need to use patient identifiable data to link ambulance service
1137 data and hospital data, to verify that different records relate to the same individual and to determine survival
1138 status for each patient.

1139

1140 b) Collect data on treatment and outcomes to hospital discharge or death (whichever occurs first) on all OHCA
1141 patients. This approval is being sought in order to access identifiable information without consent for those
1142 patients where it is not possible to obtain consent. This approach will ensure maximum data ascertainment
1143 (see section 4.6.1).

1144

1145 c) Allow NHS Digital to process patient identifiers, link them to the HES data and return the linked data back to
1146 the study team, for all enrolled patients regardless of whether or not they have provided consent for follow up.
1147 This approval is being sought to allow the health economics analysis to take place (see section 6.5).

1148

1149 **9.3 Risks and anticipated benefits**

1150

1151 Participating paramedics will benefit from additional training in resuscitation, airway management and evidence based
1152 practice during the trial. No potential harms to paramedics have been identified.

1153

1154 It is generally recognised that patients enrolled in research studies tend to have better outcomes than those not enrolled.
1155 It is possible that one study group will prove to be superior to the other, but at present clinical equipoise exists, and the
1156 trial is being undertaken to address this question. Ongoing scrutiny by the TSC and DMSC, coupled with a formal
1157 interim analysis, is designed to minimise the risk to participants, and ensure that the trial is discontinued if significant
1158 differences are identified between the two study groups.

1159

1160 Both interventions have recognised complications. These include:

1161

- 1162 • Interruptions to CPR. This is possibly more common with tracheal intubation.
- 1163 • Misplacement of the device (particularly unrecognised misplacement). This is possibly more common with
1164 tracheal intubation.

- 1165 • Regurgitation of stomach contents, and aspiration into the lungs. This is possibly more common with the i-gel
1166 SAD.
1167 • Dislodgement of the device during ongoing resuscitation and/or patient transport. This is possibly more
1168 common with the i-gel SAD.
1169 • Trauma to the patient’s airway. This is likely to occur with similar frequency with both devices.
1170 • Device failure. This is likely to occur with similar frequency with both devices.
1171

1172 Society will benefit from the evidence generated from this study, which will indicate the best initial airway
1173 management in OHCA. This will in turn benefit future OHCA patients in the UK and overseas, by reducing the risk of
1174 death and disability following OHCA, and potentially improving the use of healthcare resources.

1175

1176 **9.4 Informing potential paramedics of possible benefits and known risks**

1177

1178 Information about possible benefits and risks of participation will be described in the paramedic PIL.
1179

1180 **9.5 Obtaining informed consent from paramedics**

1181

1182 Eligible paramedics will be sent an invitation letter, paramedic PIL and consent form. If the paramedic has any
1183 questions or concerns that they would like to raise, contact details of the study co-ordinator or local research paramedic
1184 will be provided in the paramedic PIL.

1185

1186 If individual paramedics are interested in participating in the study, they will be invited to attend a training session (see
1187 section 5.3.1), where generic training on resuscitation and the study procedures, including data collection, will take
1188 place and paramedics will also have the opportunity to ask any questions. At this point in the training session
1189 paramedics will be asked to provide written informed consent. Any paramedics who do not wish to consent to taking
1190 part in the study will be free to leave the training session at this point without prejudice.

1191

1192 Paramedics, who do consent, will be given a copy of their consent form to keep for their own records and the original
1193 will be retained for the study records. Paramedics consenting to the study will then be randomised to one of the two
1194 trial groups (i-gel or intubation) and the remainder of the training session will be trial group specific.

1195

1196 **9.6 Informing potential study participants of possible benefits and known risks**

1197

1198 At the point of consent, patients will have already received treatment for the cardiac arrest. There are no anticipated
1199 disadvantages or risks to participants consenting to the follow up phase of the study.

1200

1201 **9.7 Obtaining informed consent from participants**

1202

1203 When a cardiac arrest occurs it is not possible to obtain consent from the patient. Consent will be obtained
1204 retrospectively (deferred consent) if the patient survives to hospital admission and recovers sufficiently to be able to
1205 understand the study and its aims. If the patient does not survive consent will not be sought retrospectively.

1206

1207 The timing of the approach is important and needs to balance the need to inform at an early opportunity while
1208 determining accurately which patients have died, and which are potentially able to give consent. Consent will usually
1209 be obtained soon after discharge from ICU. A patient PIL will be provided and written consent/assent obtained. Once
1210 written consent/assent has been obtained the patient’s general practitioner will be sent an information letter detailing
1211 the study.

1212

1213 **9.7.1 Consent process for surviving patients with capacity**

1214

1215 All enrolled patients that survive to hospital admission will be followed-up by a member of hospital staff or a member
1216 of the research team, who will consult with clinical staff caring for that individual to determine the optimal time to
1217 approach the patient and/or their family to seek consent/assent for further follow-up and data collection. Ward-based
1218 clinical staff will also be asked to confirm that survivors have mental capacity before they are approached, and where
1219 necessary these clinical staff will introduce the study and research team members to patients.

1220

1221 All surviving potential participants will be given or sent a patient PIL, approved by the REC describing the study, and
1222 will be invited to participate in the follow-up phase.

1223

1224 Where possible, survivors will be approached whilst they are recovering. Usually, patients stay in the ICU or CCU for
1225 2-5 days after their OHCA, following which they are transferred to a general medical ward. Our patient and public
1226 research advisory group has advised against approaching patients for consent whilst they are still on ICU/CCU since
1227 consent is not a time critical process, and has no impact upon the patient's treatment or care.

1228

1229 The individual taking consent will confirm the patient's eligibility, answer any questions and allow the patient a period
1230 of time to go over the PIL and consult others. They will then return at a later time, as guided by the patient but usually
1231 after at approximately 24 hours have elapsed, to take written informed consent if the patient decides to participate. The
1232 name and address of those who consent to active follow-up will be captured at this time.

1233

1234 There will be 3 different consent options:

1235

1236 A. The patient can consent to ACTIVE follow-up; where both routine data sources will be used and the patient
1237 will be actively followed up at discharge, 3 and 6 months after the index OHCA. Quality of life and mRS
1238 score will be collected at these time points.

1239

1240 B. The patient can consent to passive follow-up; with this option only routine data will be collected and the
1241 patient will not be contacted again about the study.

1242

1243 C. If a patient does not wish to be followed up they can select the option; I decline to take any further part in the
1244 study. I do not wish to be contacted again (with this option no further data collection will take place).

1245

1246 We will ask all OHCA survivors to sign the consent form, selecting which method of follow up they would prefer
1247 (three different options on the consent form). Patients will be given a copy of the consent form for their own records,
1248 one copy will be placed in the patient's medical records and the original copy will be kept in the secure study records.

1249

1250 If a patient does not wish to complete the consent form a record of this will be taken and these patients will
1251 automatically be assigned to option C where no further data collection will take place.

1252

1253 In the rare event of a patient with capacity being unable to physically complete the consent form, verbal consent will
1254 be accepted and will be documented on the study specific consent form and in the medical notes. An independent
1255 member of staff (e.g. a registered nurse caring for that patient) will be asked to annotate the consent form to indicate
1256 that they have witnessed verbal consent.

1257

1258 There will be a few cases where patients are discharged from hospital (either to another facility or their usual place of
1259 residence) before the consent process can be completed. We will post a PIL to these patients, with a covering letter,
1260 patient consent form. We will provide contact details of the local research nurse so that the patient can easily contact
1261 someone if they have any questions about the study.

1262

1263 If the patient wishes to participate, we will ask them to sign the consent form, keep one copy for their own records and
1264 we will ask for the other two copies to be returned in a prepaid envelope. If a patient fails to respond within 28-days of
1265 the information being sent we will assume that they do not consent to follow-up, and no further data will be collected.

1266

1267 **9.7.2 Surviving patients who lack capacity**

1268

1269 For patients lacking capacity (as assessed by the clinical staff caring for the patient on the ward) an opinion will be
1270 sought from a close relative or friend (“consultee”), who will be asked to provide advice about the patient’s wishes and
1271 feelings, and whether they would wish to participate in the follow-up phase, according to the provisions of the Mental
1272 Capacity Act (2005). This personal consultee will also be identified by ward-based clinical staff caring for the patient,
1273 and these staff will introduce the study and local research team member to the prospective consultee as required.
1274 Modified PIL and response forms specifically designed for a consultee will be used. Any questions raised will be
1275 addressed by the research team.

1276

1277 If the identified individual agrees to act as a consultee we will ask them to sign the response form. The consultee will
1278 be asked to advise which method of follow up the patient would prefer (see section 9.7.1). On signing the response
1279 form, the consultee will be given a copy of the form to keep for their own records, a second copy will be placed in the
1280 patient’s medical records and a third copy will be retained in a secure location by the study team.

1281

1282 If a patient without capacity is discharged from hospital (either to another facility or their usual place of residence)
1283 before the opinion of a personal consultee can be sought we will identify a personal consultee through communication
1284 with the clinical staff responsible for that patient’s care whilst in hospital. The modified PIL and a response form will
1285 then be sent to the potential personal consultee with a covering letter. We will provide contact details for the consultee
1286 to get in touch with the study team so that they have an opportunity to ask any questions they may have.

1287

1288 If a personal consultee fails to respond within 28-days of the information being sent we will assume that the patient
1289 would not consent to follow-up, and no further data will be collected.

1290

1291 **9.8 Co-enrolment**

1292

1293 Because of the urgency of treatment there is no opportunity to identify whether a patient is already enrolled in a
1294 research study, and so it will be assumed that this is not the case*. Since the duration of intervention is very short it is
1295 highly unlikely that inadvertent co-enrolment will lead to any difficulties. Patients who have been enrolled in this study
1296 could be considered for co-enrolment in subsequent research (for example trials occurring in ICU), providing the
1297 combined follow-up procedures do not conflict, and are not considered unduly arduous. Participants may be enrolled in
1298 observational studies.

1299

1300 *The only exception to this would be where an attending paramedic may have already have enrolled the patient in
1301 another pre-hospital randomised trial; in these rare circumstances the patient will be excluded from taking part in the
1302 AIRWAYS-2 study.

1303

1304 **10. RESEARCH GOVERNANCE**

1305

1306 This study will be conducted in accordance with:

- 1307 • The Medicine for Human Use (Clinical Trial) Regulations 2004
- 1308 • The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006
- 1309 • International Conference for Harmonisation of Good Clinical Practice (ICH GCP) guidelines
- 1310 • Research Governance Framework for Health and Social Care
- 1311 • The trial will be subject to the requirements of the Mental Capacity Act 2005.

1312

1313 **10.1 Sponsor approval**
1314

1315 Any amendments to the trial documents must be approved by the sponsor prior to submission to the REC.
1316

1317 **10.2 NHS approval**
1318

1319 Approval from the local NHS Trust (s) is required prior to the start of the trial.
1320

1321 Any amendments to the trial documents approved by the REC will be submitted to the Trust for information or
1322 approval as required.
1323

1324 **10.3 Investigators' responsibilities**
1325

1326 The local principal investigators situated within each of the ambulance will be required to ensure that local research
1327 approvals have been obtained by their ambulance trust and that any contractual agreements required have been signed
1328 off by all parties before recruiting any participant. They will be required to ensure compliance to the protocol and
1329 study manual throughout the duration of the study.
1330

1331 The local principal Investigators will be required to allow access to study documentation or source data on request for
1332 monitoring visits and audits performed by the Sponsor or CTEU Bristol or any regulatory authorities. They will be
1333 required to read, acknowledge and inform their trial team of any amendments to the trial documents approved the REC
1334 that they receive and ensure that the changes are complied with.
1335

1336

1337 **10.4 Monitoring by sponsor**
1338

1339 The study will be monitored and audited in accordance with the Sponsor's policy, which is consistent with the
1340 Research Governance Framework and the Medicines for Human Use (Clinical Trials) Regulations 2004. All study
1341 related documents will be made available on request for monitoring and audit by the sponsor (or CTEU Bristol if they
1342 have been delegated to monitor see 7.2.2), the relevant REC and for inspection by other licensing bodies.
1343

1344 **10.5 Indemnity**
1345

1346 This is an NHS-sponsored research study. For NHS sponsored research HSG(96)48 reference no. 2 refers. If there is
1347 negligent harm during the clinical trial when the NHS body owes a duty of care to the person harmed, NHS Indemnity
1348 covers NHS staff, medical academic staff with honorary contracts, and those conducting the trial. NHS Indemnity does
1349 not offer no-fault compensation and is unable to agree in advance to pay compensation for non-negligent harm. Ex-
1350 gratia payments may be considered in the case of a claim.
1351

1352 **10.6 Clinical Trial Authorisation**
1353

1354 The intervention is not classed as an investigational medicinal product as the I-gel device is CE marked and is being
1355 used with its license, therefore a Clinical Trial Authorisation from the MHRA is not required.
1356
1357

1358 **11. DATA PROTECTION AND PARTICIPANT CONFIDENTIALITY**

1359

1360 **11.1 Data protection**

1361

1362 Data will be collected and retained in accordance with the UK Data Protection Act 1998.

1363

1364

1365 **11.2 Data handling, storage and sharing**

1366

1367 **11.2.1 Data handling**

1368

1369 Data will be entered onto a purpose designed database and data validation and cleaning will be carried out throughout
1370 the trial. Standard operating procedures (SOPs) for database use, data validation and data cleaning will be available
1371 and regularly maintained.

1372

1373 Access to the database will be via a secure password-protected web-interface (NHS clinical portal). Study data
1374 transferred electronically between the University of Bristol and the NHS will only be transferred via a secure NHS net
1375 network in an encrypted form.

1376

1377 Data from ambulance trust and receiving hospitals will be submitted to the CTEU Bristol either directly into the
1378 database which will be accessed by via the NHS portal or by secure fax or by recorded delivery.

1379

1380 **11.2.2 Data storage**

1381

1382 All study documentation will be retained in a secure location during the conduct of the study and for 5 years after the
1383 end of the study, when all patient identifiable paper records will be destroyed by confidential means.

1384

1385 Where trial related information is documented in the medical records – those records will be identified by a ‘Do not
1386 destroy before dd/mm/yyyy’ label where the date is five years after the last patient last visit.

1387

1388 Access to stored information will be restricted to authorised personnel. Data forms will be stored in a lockable filing
1389 cabinet in a secure room, to which access is restricted to authorised personnel. Electronic data will be stored in a
1390 secure area of an NHS hospital server.

1391

1392 Any data that are transferred out of the secure environment (for example for statistical analysis) will be anonymised
1393 and individual participants identified by study number only.

1394

1395 In compliance with the Medical Research Policy (MRC) on Data Preservation, relevant ‘meta’-data about the trial and
1396 the full dataset, but without any participant identifiers other than the unique participant identifier, will be held
1397 indefinitely (University server). A secure electronic ‘key’ with a unique participant identifier, and key personal
1398 identifiers (e.g. name, date of birth and NHS number) will also be held until the study database has been locked, all
1399 data validated and the results from the study published. These identifiers will be held in a separate file and in a
1400 physically different location (NHS hospital server).

1401

1402 **11.2.3 Data sharing**

1403

1404 Data will not be made available for sharing until after publication of the main results of the study. Thereafter,
 1405 anonymised individual patient data will be made available for secondary research, conditional on assurance from the
 1406 secondary researcher that the proposed use of the data is compliant with the MRC Policy on Data Preservation and
 1407 Sharing regarding scientific quality, ethical requirements and value for money. A minimum requirement with respect
 1408 to scientific quality will be a publicly available pre-specified protocol describing the purpose, methods and analysis of
 1409 the secondary research, e.g. a protocol for a Cochrane systematic review.

1410

1411

1412 12. DISSEMINATION OF FINDINGS

1413

1414 A dissemination strategy will be implemented that includes electronic dissemination of the study outputs to ambulance
 1415 services in the UK and overseas, to acute trusts, and through a publicly accessible website. We will also feedback to all
 1416 stakeholder groups and will present our findings at relevant conferences and at international ambulance, resuscitation
 1417 and emergency care meetings.

1418

1419 Findings will be published in high-impact journals, presented at conferences, circulated in newsletters and will also be
 1420 shared with international groups responsible for the generation of resuscitation guidelines (see below).

1421

1422 We will pay particular attention to dissemination to the public and ambulance services, since this is where the findings
 1423 will be most readily implemented. In particular there will be important implications for paramedic training and skills
 1424 retention, and we will ensure that we make our training materials freely available for future adaptation and use.

1425

1426 Because resuscitation for OHCA is strongly protocol driven, we anticipate that the findings will be readily adopted into
 1427 practice through changes to accepted guidelines. This will lead to tangible benefits to future OHCA patients, and may
 1428 also benefit ambulance services by enabling rationalisation of training and equipment, as well as having the potential
 1429 to prove cost effective for the NHS and society as a whole. We are therefore examining cost effectiveness as an
 1430 integral component of this research.

1431

1432

1433 13. AMENDMENTS TO PROTOCOL

1434

Amendment number (i.e. REC and/or MHRA amendment number)	Previous version	Previous date	New version	New date	Brief summary of change	Date of ethical approval (or NA if non-substantial)
Pre-ethical approval	1.0	01/08/2014	2.0	16/09/2014	Reference to a 12 month follow up has been removed, wording paramedic arrival change to 'at patient's side' rather than 'at scene'. Patient exclusion criteria updated to include opt-of trial. The Cognitive function using CPC has been removed. Data Collection; clarified that the screening log of all patients that have an	

					OHCA should only include patients for whom resuscitation is attempted. The statistical analysis has been modified to account for retrospective exclusion	
2	2.0	08/01/2015	3.0	12/01/2015	Inclusion/exclusion criteria added (section 4.4.2), more detail added about 1° and 2° outcome (section 4.6.1), extra strata added to randomisation (Section 5.1), End of trial definition updated (section 5.5), Section 5.6.2, 5.7, 5.11 & 6.5 details better defined.	
3	3.0	12/01/2015	4.0	13/04/2015	Inclusion/exclusion criteria modified (section 4.4.1 & 4.4.2), clarity added to primary outcome (section 4.6.1), section 5.3.2 the word quantitative has been removed when describing carbon dioxide monitoring. Section 6.5, reference to comparative costs of pre-registration training have been removed.	
6	5.0	27/07/2015	6.0	21/12/2017	Added wording to explain additional requirements from the CAG	

1435

1436

14. REFERENCES

1437

1438

1. Woollard, M., *Public access defibrillation: a shocking idea?* Journal of Public Health Medicine, 2001. **23**(2): p. 98-102.
2. Health, L.D.o., *Ambulance quality indicators data downloads*. 2012.
3. Berdowski, J., et al., *Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies*. Resuscitation, 2010. **81**(11): p. 1479-1487.
4. England, N., *Ambulance quality indicators*. 2013.
5. London Ambulance Service, L., Clinical Audit and Research Unit 2012, *Cardiac Arrest Annual Report*. 2011/12.
6. (ICNARC), I.C.N.A.a.R.C., *Casemix programme*, 2013.
7. Lim, C., et al., *The neurological and cognitive sequelae of cardiac arrest*. Neurology, 2004. **63**(10): p. 1774-1778.
8. Sauve, M.J., et al., *Factors associated with cognitive recovery after cardiopulmonary resuscitation*. American journal of critical care : an official publication, American Association of Critical-Care Nurses, 1996. **5**(2): p. 127-39.
9. de Vos, R., et al., *Quality of survival after cardiopulmonary resuscitation*. Archives of Internal Medicine, 1999. **159**(3): p. 249-254.

1453

- 1454 10. Wachelder, E.M., et al., *Life after survival: Long-term daily functioning and quality of life after an out-of-*
1455 *hospital cardiac arrest.* Resuscitation, 2009. **80**(5): p. 517-522.
- 1456 11. Yeh, S.T., et al., *Oxygen requirement during cardiopulmonary resuscitation (CPR) to effect return of*
1457 *spontaneous circulation.* Resuscitation, 2009. **80**(8): p. 951-955.
- 1458 12. Idris, A.H., et al., *DOES HYPOXIA OR HYPERCARBIA INDEPENDENTLY AFFECT RESUSCITATION*
1459 *FROM CARDIAC-ARREST.* Chest, 1995. **108**(2): p. 522-528.
- 1460 13. Cavus, E., et al., *Laryngeal tube S II, ProSeal laryngeal mask, and EasyTube during elective surgery: a*
1461 *randomized controlled comparison with the endotracheal tube in nontrained professionals.* European Journal
1462 of Anaesthesiology, 2009. **26**(9): p. 730-735.
- 1463 14. Nolan, J.P. and J. Soar, *Airway techniques and ventilation strategies.* Current Opinion in Critical Care, 2008.
1464 **14**(3): p. 279-286.
- 1465 15. van Alem, A.P., et al., *Cognitive impairment in survivors of out-of-hospital cardiac arrest.* American Heart
1466 Journal, 2004. **148**(3): p. 416-421.
- 1467 16. Becker, L.B., et al., *Primary Outcomes for Resuscitation Science Studies A Consensus Statement From the*
1468 *American Heart Association.* Circulation, 2011. **124**(19): p. 2158-U267.
- 1469 17. Wang, H.E., et al., *Preliminary experience with a prospective, multi-centered evaluation of out-of-hospital*
1470 *endotracheal intubation.* Resuscitation, 2003. **58**(1): p. 49-58.
- 1471 18. Wang, H.E., et al., *Interruptions in Cardiopulmonary Resuscitation From Paramedic Endotracheal*
1472 *Intubation.* Annals of Emergency Medicine, 2009. **54**(5): p. 645-652.
- 1473 19. Lyon, R.M., et al., *Field intubation of cardiac arrest patients: a dying art?* Emergency Medicine Journal,
1474 2010. **27**(4): p. 321-323.
- 1475 20. Kurola, J., et al., *Airway management in cardiac arrest - comparison of the laryngeal tube, tracheal*
1476 *intubation and bag-valve mask ventilation in emergency medical training.* Resuscitation, 2004. **61**(2): p. 149-
1477 153.
- 1478 21. Verghese, C. and J.R. Brimacombe, *Survey of laryngeal mask airway usage in 11,910 patients: Safety and*
1479 *efficacy for conventional and nonconventional usage.* Anesthesia and Analgesia, 1996. **82**(1): p. 129-133.
- 1480 22. Cook T, H.B., *Supraglottic airway devices: recent advances.* Continuing Education in Anaesthesia, Critical
1481 Care & Pain, 2011. **11**: p. 56-51.
- 1482 23. Nicholson A, L.S., Cook TM, Smith AF, *Supraglottic airway devices versus tracheal intubation for airway*
1483 *management during general anaesthesia in obese patients (Protocol).* Cochrane Database, 2012(9).
- 1484 24. Soar, J. and J.P. Nolan, *Airway management in cardiopulmonary resuscitation.* Current Opinion in Critical
1485 Care, 2013. **19**(3): p. 181-187.
- 1486 25. Wang, H.E. and D.M. Yealy, *Managing the Airway During Cardiac Arrest.* Jama-Journal of the American
1487 Medical Association, 2013. **309**(3): p. 285-286.
- 1488 26. Duckett, J., et al., *Introduction of the i-gel supraglottic airway device for prehospital airway management in a*
1489 *UK ambulance service.* Emergency Medicine Journal, 2014. **31**(6): p. 505-507.
- 1490 27. Haeske, D., et al., *Performance of the i-gel (TM) during pre-hospital cardiopulmonary resuscitation.*
1491 Resuscitation, 2013. **84**(9): p. 1229-1232.
- 1492 28. Wang, H.E., et al., *Endotracheal intubation versus supraglottic airway insertion in out-of-hospital cardiac*
1493 *arrest.* Resuscitation, 2012. **83**(9): p. 1061-1066.
- 1494 29. Elliott, V.J., D.L. Rodgers, and S.J. Brett, *Systematic review of quality of life and other patient-centred*
1495 *outcomes after cardiac arrest survival.* Resuscitation, 2011. **82**(3): p. 247-256.
- 1496 30. Rittenberger, J.C., et al., *Association between Cerebral Performance Category, Modified Rankin Scale, and*
1497 *discharge disposition after cardiac arrest.* Resuscitation, 2011. **82**(8): p. 1036-1040.
- 1498 31. Arrich, J., et al., *Factors associated with a change in functional outcome between one month and six months*
1499 *after cardiac arrest A retrospective cohort study.* Resuscitation, 2009. **80**(8): p. 876-880.
- 1500 32. Wissenberg, M., et al., *Association of National Initiatives to Improve Cardiac Arrest Management With Rates*
1501 *of Bystander Intervention and Patient Survival After Out-of-Hospital Cardiac Arrest.* Jama-Journal of the
1502 American Medical Association, 2013. **310**(13): p. 1377-1384.
- 1503 33. Hostler, D., et al., *Effect of real-time feedback during cardiopulmonary resuscitation outside hospital:*
1504 *prospective, cluster-randomised trial.* British Medical Journal, 2011. **342**.
- 1505 34. Christenson, J., et al., *Chest Compression Fraction Determines Survival in Patients With Out-of-Hospital*
1506 *Ventricular Fibrillation.* Circulation, 2009. **120**(13): p. 1241-1247.
- 1507 35. Lyon, R.M., et al., *Resuscitation quality assurance for out-of-hospital cardiac arrest - Setting-up an*
1508 *ambulance defibrillator telemetry network.* Resuscitation, 2010. **81**(12): p. 1726-1728.
- 1509 36. Turner, J., et al., *A randomised controlled trial of prehospital intravenous fluid replacement therapy in*
1510 *serious trauma.* Health technology assessment (Winchester, England), 2000. **4**(31): p. 1-57.

- 1511 37. Snooks, H., et al., *Support and assessment for fall emergency referrals (SAFER 2) research protocol: cluster*
1512 *randomised trial of the clinical and cost effectiveness of new protocols for emergency ambulance paramedics*
1513 *to assess and refer to appropriate community-based care.* BMJ open, 2012. **2**(6).
- 1514 38. Perkins, G.D., et al., *Prehospital randomised assessment of a mechanical compression device in cardiac*
1515 *arrest (PaRAMeDIC) trial protocol.* Scandinavian Journal of Trauma Resuscitation & Emergency Medicine,
1516 2010. **18**.
- 1517 39. Health, D.o., *Technical Guidance for the 2011/12 Operating Framework.* 2012.
- 1518 40. Warwick, U.o., *Overview of the OHCAO project.*
- 1519 41. Tagami, T., et al., *Implementation of the Fifth Link of the Chain of Survival Concept for Out-of-Hospital*
1520 *Cardiac Arrest.* Circulation, 2012. **126**(5): p. 589-+.
- 1521 42. Savio, K., et al., *Reliability of the modified Rankin Scale applied by telephone.* Neurology international, 2013.
1522 **5**(1): p. e2-e2.
- 1523 43. Janssen, P.M., et al., *Comparison of Telephone and Face-to-Face Assessment of the Modified Rankin Scale.*
1524 *Cerebrovascular Diseases,* 2010. **29**(2): p. 137-139.
- 1525 44. McPhail, S., et al., *Telephone reliability of the Frenchay Activity Index and EQ-5D amongst older adults.*
1526 *Health and Quality of Life Outcomes,* 2009. **7**.
- 1527 45. Longstreth, W.T., Jr., et al., *Two simple questions to assess neurologic outcomes at 3 months after out-of-*
1528 *hospital cardiac arrest: Experience from the Public Access Defibrillation Trial.* Resuscitation, 2010. **81**(5): p.
1529 530-533.
- 1530 46. Taljaard, M., et al., *The Ottawa Statement on the ethical design and conduct of cluster randomised trials:*
1531 *precis for researchers and research ethics committees.* Bmj-British Medical Journal, 2013. **346**.
- 1532 47. Campbell, M.K., et al., *CONSORT statement: extension to cluster randomised trials.* British Medical Journal,
1533 2004. **328**(7441): p. 702-708.
- 1534 48. Excellence, N.I.f.H.a.C., *Guide to the methods of technology appraisal.* 2013.
- 1535 49. Dolan, P., *Modeling valuations for EuroQol health states.* Medical Care, 1997. **35**(11): p. 1095-1108.
- 1536 50. EuroQol, G., *EuroQol--a new facility for the measurement of health-related quality of life.* Health policy
1537 (Amsterdam, Netherlands), 1990. **16**(3): p. 199-208.
- 1538 51. Herdman, M., et al., *Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-*
1539 *5L).* Quality of Life Research, 2011. **20**(10): p. 1727-1736.
- 1540 52. Dolan P, G.C., Kind P, Williams A., *A Social Tariff for Euroqol: Results from a UK General Population*
1541 *Survey.* CHE Discussion Paper 138 University of York, 1995.
- 1542 53. Briggs, A., et al., *Missing presumed at random: cost-analysis of incomplete data.* Health Economics, 2003.
1543 **12**(5): p. 377-392.
- 1544 54. Gray A, C.P., Wolstenholme J and Wordsworth S, *Applied Methods of Cost-Effectiveness Analysis in Health*
1545 *Care* Handbooks in Health Economic Evaluation Series, ed. , ed. O.O.U. Press. 2011.
- 1546 55. Gomes, M., et al., *Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster*
1547 *Randomized Trials: A Systematic Review and Checklist for Critical Appraisal.* Medical Decision Making,
1548 2012. **32**(1): p. 209-220.
- 1549 56. Gomes, M., et al., *Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized*
1550 *Trials.* Medical Decision Making, 2012. **32**(2): p. 350-361.
- 1551 57. Excellence, N.I.f.H.a.C., *Social value judgements: Principles for the development of NICE guidance.* 2nd
1552 Edition 2008.
- 1553
- 1554
- 1555
- 1556
- 1557

1558

1559 **2. Statistical analysis plan (version 2)**

1560

1561

1562

AIRWAYS-2
Statistical Analysis Plan

1563

1564

1565

1566

1567

1568

1569

1570

	NAME	TITLE	SIGNATURE	DATE
Author	Lauren Scott, Helena Smartt and Michelle Lazaroo	Medical statisticians		19/04/2018
Authoriser	Chris Rogers	CTEU co-director		19/04/2018

1571

Effective Date:	19/04/2018
------------------------	------------

1572

1573

1574

1575	Table of contents	
1576	List of abbreviations	41
1577	1. Introduction to SAP.....	42
1578	1.1 Scope.....	42
1579	1.2 Editorial changes	42
1580	1.3 SAP document approval.....	42
1581	1.4 Skeleton tables and figures.....	42
1582	2. Study background and objectives.....	43
1583	2.1 Study background.....	43
1584	2.2 Study objectives	43
1585	2.3 Primary outcome	43
1586	2.4 Secondary outcomes.....	43
1587	2.5 Changes to the study objectives during the course of the study.....	44
1588	2.6 Changes to the study outcomes during the course of the study.....	44
1589	3. Study population.....	45
1590	3.1 Consent.....	45
1591	3.2 Flow of participants.....	45
1592	3.3 Characteristics of non-study patients	45
1593	3.4 Randomisation.....	45
1594	3.5 Protocol deviations	46
1595	3.6 Withdrawals.....	46
1596	3.7 Analysis populations	46
1597	3.8 Safety population.....	47
1598	4. DATA SOURCES.....	48
1599	5. Derivations	49
1600	5.1 Primary outcome	49
1601	5.2 Compression Fraction.....	49
1602	5.3 EQ-5D	49
1603	5.4 Other variables	49
1604	6. Statistical analyses.....	57
1605	6.1 Baseline data.....	57
1606	6.2 Primary and secondary outcome data.....	57
1607	6.2.1 Adjustment in models	57
1608	6.2.2 Data presentation and analysis models	57
1609	6.2.3 Statistical significance	58
1610	6.2.4 Model assumptions	59
1611	6.2.5 Subgroup analyses	59

1612 6.2.6 Sensitivity analyses59

1613 6.2.7 Missing data59

1614 6.2.8 Multiple testing59

1615 6.3 Safety data60

1616 7. Amendments to the SAP60

1617 APPENDIX A: Skeleton tables and figures62

1618 APPENDIX B: Skeleton tables and figures78

1619

1620 **List of abbreviations**

1621

Acronym	Details
AFT	Accelerated failure time
A2	AIRWAYS-2
CI	Confidence interval
CPR	Cardiopulmonary resuscitation
CRF	Case report form
EAST	East of England ambulance service
ED	Emergency department
EMAS	East midlands ambulance service
EMS	Emergency Medical Services
ETCO2	End tidal carbon dioxide
HR	Hazard ratio
ICU	Intensive care unit
IQR	Inter quartile range
ITT	Intention to treat
mRS	Modified rankin score
NPA	Nasopharyngeal airway
OHCA	Out of hospital cardiac arrest
OPA	Oropharyngeal airway
OR	Odds ratio
QoL	Quality of life
RCT	Randomised controlled trial
ROSC	Return of spontaneous circulation
SAE	Serious adverse event
SAP	Statistical analysis plan
SD	Standard deviation
SGA	Supraglottic airway device
SWAST	South western ambulance service
TR	Time ratio
YAS	Yorkshire ambulance service

1622

1623

1624 **1. INTRODUCTION TO SAP**

1625 **1.1 Scope**

1626 This document details information regarding the statistical analysis of the completed AIRWAYS-2 (A2) trial
1627 and covers the analyses of the clinical outcomes outlined in the study protocol, with the exception of the
1628 health economic evaluation.

1629 The plan is to report the primary outcome results as soon as data on the primary and secondary outcomes to
1630 hospital discharge or 30 days are available and report the longer term outcomes to 6 months subsequently.
1631 This will allow timely reporting of the primary results to coincide with a sister trial being conducted in the
1632 United States.

1633 **1.2 Editorial changes**

1634 Any changes made to this statistical analysis plan (SAP) after approval must be clearly justified and
1635 documented as an amendment at the end of this document. The SAP should then be re-approved.

1636 **1.3 SAP document approval**

1637 The statistical CTEU co-director should authorise this document.

1638 **1.4 Skeleton tables and figures**

1639 Throughout this document references are made to any skeleton tables and figures to be used in the reporting
1640 of the study (e.g. **Figure F1** or **Table T1**). Such tables and figures can be found in **Appendix A** of this
1641 document, and are intended as a guide for trial reporting. Final versions of the tables/figures may differ: tables
1642 may be combined, and/or their layout or numbering may differ. However the content should be consistent
1643 with **Appendix A**.

1644

1645 **2. STUDY BACKGROUND AND OBJECTIVES**

1646 **2.1 Study background**

1647 AIRWAYS-2 is a randomised controlled trial (RCT) in four UK ambulance trusts (South Western Ambulance
1648 Service NHS Foundation Trust (SWAST), East of England Ambulance Service NHS Trust (EAST), East
1649 Midlands Ambulance Service NHS Trust (EMAS) and Yorkshire Ambulance Service NHS Trust (YAS)) with
1650 cluster randomisation at the paramedic level.

1651 Two advanced airway management devices for the treatment of out of hospital cardiac arrests (OHCA) are
1652 compared: the i-gel, a second generation supraglottic airway device (SGA), and tracheal intubation, currently
1653 standard practice.

1654 Ambulance staff performing the airway management are unable to be blinded to allocation but the patients
1655 and research staff assessing all outcomes post hospital admission (including the primary outcome) will be
1656 blinded.

1657 **2.2 Study objectives**

1658 1. To estimate the difference in the primary outcome of mRS at hospital discharge or 30 days post OHCA,
1659 whichever comes first, between groups of patients managed by paramedics randomised to use either the i-gel
1660 or intubation as their initial advanced airway management strategy following OHCA.

1661 2. To estimate differences in secondary outcome measures relating to airway management, hospital stay and
1662 recovery at 3 and 6 months between groups of patients managed by paramedics randomised to use either the i-
1663 gel or intubation.

1664 3. To estimate the comparative cost effectiveness of the i-gel and intubation, including estimating major in
1665 hospital resources and subsequent costs (length of stay, days of intensive and high dependency care, etc.) in
1666 each group. This objective will not be covered in this analysis.

1669 **2.3 Primary outcome**

1670 The primary outcome is mRS assessed at hospital discharge (or 30 days post OHCA if patient remains in
1671 hospital until this time). The mRS incorporates survival status and will be analysed as good recovery (scores 0
1672 to 3) compared to poor recovery/death (scores 4 to 6).

1673 **2.4 Secondary outcomes**

1674 The protocol includes the secondary outcomes listed below (a health economic outcome is also listed in the
1675 protocol but excluded here).

1676 All enrolled patients:

- 1677 1. Initial ventilation success, defined as visible chest rise and end tidal carbon dioxide (ETCO₂) at the first
1678 or second attempt¹.
- 1679 2. Regurgitation/aspiration.
- 1680 3. Loss of a previously established airway.
- 1681 4. Actual sequence of airway interventions delivered.
- 1682 5. Chest compression fraction (two ambulance regions only, added part way through the trial)
- 1683 6. Return of spontaneous circulation (ROSC)*.
- 1684 7. Airway management in place when first ROSC was achieved or the resuscitation was discontinued.
- 1685

1686 Patients who survive to admission to hospital (estimated 20% of enrolled patients):

- 1687 8. Length of intensive care stay.
- 1688 9. Length of hospital stay.

¹ Note: chest rise and ETCO₂ is the definition on the CRF, but ETCO₂ is not included in the definition given in the protocol. Also, the protocol does not state whether success should be based on the first attempt only or the first or second attempt.

1689	
1690	Patients who survive to hospital discharge and consent to active follow-up (estimated 9% of enrolled
1691	patients):
1692	10. Quality of life (using the EQ-5D) at hospital discharge.
1693	
1694	Patients who survive beyond hospital discharge and consent to active follow-up:
1695	11. Time to death or last follow-up
1696	12. Modified Rankin score at 3 and 6 months following OHCA
1697	13. Quality of life (using the EQ-5D) at 3 and 6 months following OHCA.
1698	<i>* note: this outcome includes both ROSC during advanced airway management attempts carried out by an</i>
1699	<i>AIRWAYS-2 paramedic and on ED arrival for those patients conveyed to ED</i>
1700	2.5 Changes to the study objectives during the course of the study
1701	N/A
1702	2.6 Changes to the study outcomes during the course of the study
1703	There have been no outcomes added or removed, but outcomes that were not clearly defined in the protocol
1704	have been reviewed and precise definitions have been agreed. These include definitions for secondary
1705	outcomes 1 to 7, the addition of time to death as a more informative means of comparing length of ICU and
1706	hospital stays and two analyses of survival at 72h (as binary and time to event outcomes) . Definitions are
1707	given in Section 5.
1708	

1709 **3. STUDY POPULATION**

1710 The study population is patients aged 18 or over experiencing a non-traumatic OHCA. Enrolled patients must
1711 be attended by an A2 paramedic who is first or second at the patient's side and resuscitation must be
1712 commenced or continued by ambulance staff or responder. For specific inclusion/exclusion criteria and details
1713 of study patients and paramedics see template **Figures F1** and **F2**. 'Trial patients' are those who are
1714 resuscitated, attended by an A2 paramedic and meet the eligibility criteria.

1715 Recruitment over time against targets will be presented by trust and overall (**Figures F3, F4 and F5**).

1716 In the context of this trial, 'advanced airway management' refers to the use of intubation, the i-gel device or
1717 other supraglottic airway devices.

1718 **3.1 Consent**

1719 Due to the emergency nature of the trial, we have ethical approval to enrol patients without consent and seek
1720 consent for further participation from patients who survive to discharge from intensive care (ICU). We have
1721 approval to retain data collected up to the point of approach (or death if this occurs before approach) as well
1722 as mRS at hospital discharge or death for all patients regardless of whether they consent.

1723 Patients may choose one of the following three options when presented with the trial information and consent
1724 form:

1725 Active follow-up - Routine data will be utilised and the patient will be actively followed up at hospital
1726 discharge, and 3 and 6 months after the index OHCA. Quality of life and mRS will be collected at these three
1727 time points.

1728 Passive follow-up - Only routine data will be collected and the patient will not be contacted again about the
1729 study.

1730 Does not wish to participate – No further data collection will take place.

1731 **3.2 Flow of participants**

1732 Participant and paramedic flow will be described via flowcharts (see **Figures F1** and **F2**). Follow-up will
1733 occur at three and six months post OHCA (target ± 4 weeks) for patients who consent to active follow-up.

1734 **3.3 Characteristics of non-study patients**

1735 All resuscitated patients who are attended by an A2 paramedic and meet the eligibility criteria are
1736 automatically enrolled in the study and classed as trial patients. Key demography and initial cardiac arrest
1737 details are collected for all resuscitated patients, including those who are not attended by an A2 paramedic or
1738 are ineligible; these details will be described for trial and non-trial patients (**Table T1**). Resuscitated non-trial
1739 patients are referred to as population 0 in this document.

1740 **3.4 Randomisation**

1741 Paramedics are randomised (1:1 allocation) to either the i-gel or intubation group using an in-house internet-
1742 based system. Randomisation is stratified by ambulance trust, clinical experience (greater than or equal to 5
1743 years full-time operational experience verses less than 5 years full-time operational experience) and the
1744 location of the paramedic's base ambulance station (greater than or equal to 5 miles verses less than 5 miles
1745 from the nearest hospital with an emergency department that receives cardiac arrest patients; this is a proxy
1746 for urban vs. rural location).

1747 To avoid bias that may be introduced by the cluster randomisation all patients who are resuscitated, attended
1748 by an A2 paramedic and meet the eligibility criteria are automatically enrolled in the trial and considered trial
1749 patients. If the attending paramedic forgets to treat a patient according to the A2 protocol or chooses not to
1750 follow the protocol, the patient is still enrolled in the trial and the attending A2 paramedic is still considered
1751 to be the enrolling paramedic and will be asked to complete a CRF; these patients are noted on the database as
1752 not 'consciously' enrolled and if they did not treat the patient according to their allocation will be counted as a
1753 protocol deviation (see section 3.5).

1754 **3.5 Protocol deviations**

1755 The following protocol deviations will be considered:

- 1756 • A patient did not meet the study eligibility criteria but was consciously enrolled in the study by the
1757 attending A2 paramedic. This may occur because the paramedic believed the patient to be eligible at the
1758 time of treatment but later found out they were not. These patients are not considered to be ‘trial patients’
1759 and will not be included in the study population, but such deviations will be noted.
- 1760 • The wrong paramedic enrolled the patient. According to the A2 protocol, if a patient is eligible the first
1761 A2 paramedic on scene should enrol and treat the patient. Sometimes, due to reasons such as
1762 miscommunication, a second A2 paramedic may enrol and treat the patient instead. These patients will be
1763 analysed in the allocated intervention group of the *first* A2 paramedic on scene.
- 1764 • The enrolling A2 paramedic did not perform any advanced airway management but another paramedic
1765 did. This will mostly happen if the A2 paramedic forgets to enrol the patient (and they are therefore not
1766 ‘consciously’ enrolled) or due to space issues they allow another paramedic to treat the patient. Note. If
1767 no advanced airway management was required once the enrolling paramedic arrived (e.g. because ROSC
1768 had already occurred) this is not a deviation.
- 1769 • The enrolling paramedic performed an alternative intervention to their allocation on their first advanced
1770 airway management attempt. According to the A2 protocol, enrolling paramedics should make two
1771 advanced airway management attempts with their allocated intervention before swapping to a different
1772 approach. The exception to this is solo responders in the intubation arm who are not allowed to intubate
1773 until another ambulance clinician arrives; occurrences of solo responders in the intubation arm using an i-
1774 gel before intubation will not count as a deviation but will count as a crossover in any per-protocol
1775 analyses (see section 6.2.2. for details).
- 1776 • The number of patients for whom the enrolling paramedic made only one attempt at their allocated
1777 intervention before swapping to an alternative advanced airway intervention will be noted. This is not
1778 considered a true protocol deviation as clinical reasons may have rendered a second attempt at the allocated
1779 intervention futile.

1780 The number of patients who were not ‘consciously’ enrolled in the trial will also be noted. This will often be
1781 the reason for deviations such as a patient receiving the wrong intervention, but is not a deviation in its own
1782 right.

1783 The frequency of each type of deviation will be tabulated by intervention allocation of the first A2 paramedic
1784 on scene (**Table T2 and Figure F6**). Note. It may be possible for patients to be classified as a protocol
1785 deviation for more than one reason.

1786 **3.6 Withdrawals**

1787 We have ethics approval to retain data collected up to the point of approach (after discharge from ICU) for all
1788 enrolled patients. However, patients who survive to ICU discharge and consent to participate in further data
1789 collection may later decide to withdraw. In some cases patients may be happy for data collection to continue,
1790 or for data collected up until withdrawal to be used, and therefore such patients will be included in the study
1791 analyses on an intention to treat basis (ITT). For patients who do not wish for their previously collected data
1792 to be used, we will exclude all data collected after the point of consent (i.e. ward movements, EQ-5D and
1793 follow-up data) from any analyses.

1794 Data on all withdrawals is captured on a specific case report form (CRF), and will be tabulated by allocation
1795 of the enrolling paramedic (**Table T3**).

1796 **3.7 Analysis populations**

- 1797 • **Population 1a:** The analysis population for the primary outcome (mRS at discharge/30-days) is all
1798 patients who receive resuscitation, are attended by an A2 paramedic and meet the eligibility criteria,
1799 i.e. all trial patients. This is also the analysis population for outcome 5 (chest compression fraction),
1800 but limited to two trusts and starting partway through the trial.

- 1801
- 1802
- 1803
- **Population 1b:** The analysis population for the second component of secondary outcome 6 (ROSC on ED arrival) is all patients who receive resuscitation, are attended by an A2 paramedic, meet the eligibility criteria and were conveyed to ED.
- 1804
- 1805
- 1806
- 1807
- **Population 2:** The analysis population for secondary outcomes 1 to 4, 6 and 7 (airway management details, but only covering ROSC during advanced airway management by A2 paramedic for outcome 6) is all trial patients who received at least one advanced airway management attempt by the enrolling A2 paramedic.
- 1808
- 1809
- **Population 3:** The analysis population for secondary outcome 8 (length of initial ICU stay) is all trial patients who were admitted to ICU.
- 1810
- 1811
- 1812
- **Population 4:** The analysis population for secondary outcome 9 (length of hospital stay) is all trial patients admitted to hospital who did not refuse consent (i.e. patients who either consent to active or passive follow-up or who die prior to approach).
- 1813
- 1814
- 1815
- 1816
- 1817
- **Population 5:** The analysis population for secondary outcomes 10 and 13 (EQ-5D health scores and state scores) and secondary outcomes 11 and 12 (time to death after discharge and mRS during follow-up) is all trial patients who consent to active follow-up, survive to 30 days/hospital discharge and provide relevant data for at least one of the three time points (30 days/hospital discharge, 3 months and/or 6 months).
- 1818
- 1819
- 1820
- **Population 0:** The population of patients who were resuscitated but did not become trial patients (either because they were not attended by an A2 paramedic or were ineligible). Characteristics of this population will be compared to those in population 1 (see **Table 1**).

1821 The primary analysis will be performed on an ITT basis, with patients grouped by the allocation of their first
1822 A2 paramedic on scene (see section 6.2.2 for details).

1823 **3.8 Safety population**

1824 The safety population is all trial patients (cf. analysis population for the primary outcome). Only serious
1825 adverse events which are unexpected and related to the intervention are collected, so numbers are expected to
1826 be low. These will be presented along with all intervention details.

1827

1828 **4. DATA SOURCES**

1829 A number of variables collected in AIRWAY-2 are recorded in more than one place. The following table details
1830 these variables and identifies the primary data sources and the order in which data will be selected; for example
1831 gender will be taken from Form G2, if not available from Form G2 then Form G will be used, if not available
1832 from Form G then Form E1 will be used and if not available from Form E1 then Form B will be used.

Variable	Data sources	Order of preference
Date and time of incident	Form A (CAD) Form E1 (paramedic)	Always use form A as this should be available for all patients
Gender	Form B (minimal dataset/CAD) Form E1 (paramedic) Form G (hospital details, only available for those surviving to hospital admission)	1. Form G2 2. Form G 3. Form E1 4. Form B
Date of birth (DOB)	Form B (minimal dataset/CAD) Form E1 (paramedic) Form G (hospital details, only available for those surviving to hospital admission)	1. Form G2 2. Form G 3. Form E1 4. Form B
Approximate age (Note. This variable will only be used if the date of birth is missing from all sources. If date of birth is recorded, age will be derived (see Section 5))	For patients who do not survive to hospital, age may be estimated on scene. If this is the case, this will be recorded on Form B (minimal dataset/CAD) Form E1 (paramedic)	1. Form E1 2. Form B
Presenting rhythm	Form B (minimal dataset/CAD) Form E1 (paramedic)	1. Form E1 2. Form B
Was event witnessed?	Form B (minimal dataset/CAD) Form E1 (paramedic)	1. Form E1 2. Form B
Who was the event witnessed by?	Form B (minimal dataset/CAD) Form E1 (paramedic)	1. Form E1 2. Form B
Was there bystander cardiopulmonary resuscitation (CPR)?	Form B (minimal dataset/CAD) Form E1 (paramedic)	1. Form E1 2. Form B
Date and time of hospital admission/emergency department (ED) admission	Form D (minimal dataset/paramedic contact) Form E1 (paramedic) Form G (hospital staff)	1. Form G 2. Form E1 3. Form D

1833

1834 **5. DERIVATIONS**

1835 **5.1 Primary outcome**

1836 To be calculated for all patients in population 1. Modified Rankin Score (0 to 6) at hospital discharge (or 30
1837 days post-OHCA if the patient is still in hospital at that time) is recorded for all patients who survive to
1838 hospital discharge (or 30 days post-OHCA). All trial patients who do not survive to hospital discharge (or 30
1839 days post-OHCA) will be assigned a score of 6 (dead). mRS will be dichotomised and analysed as good
1840 recovery (score 0 to 3) compared to bad recovery/death (score 4 to 6).

1841 Note. mRS is also collected at 3 and 6 months post-OHCA for patients who consent to active follow-up and
1842 will be used to calculate a dichotomised score as above and utilised for the secondary outcome of mRS up to
1843 6 months.

1844 **5.2 Compression Fraction**

1845 The compression fraction (expressed as a percentage) is measured by placing a credit-card-sized CPRCard
1846 device (Laerdal Medical, Stavanger, Norway) on the patient's chest during CPR to collect chest compression
1847 data. Data are downloaded from the card and interpreted using a CPRCard Laerdal Card reader ID CPR30-
1848 LA (FEIG Electronic, Germany) and a standard algorithm.

1849 **5.3 EQ-5D**

1850 To be calculated for all patients in population 5 at up to three time points: hospital discharge/30days post
1851 OHCA, 3 months post OHCA and 6 months post OHCA.

1852 A five digit 'state' score will be derived from the mobility, self-care, usual activities, pain/discomfort and
1853 anxiety/depression scores using the following:

1854 State = 10000*mobility score + 1000*self-care score + 100*usual activities score + 10*pain/discomfort score
1855 + anxiety/depression score

1856 Each state will then be assigned a single summary index score according to a standard scale. These index
1857 scores are numerical and range from -0.59 to 1.00, with a score of 1.00 denoting perfect health. If any of the
1858 five raw scores are missing, the state score and index score will be missing.

1859 The EQ-5D questionnaire visual analogue scales are also collected. Such scores range from 0 to 100 (with
1860 higher scores denoting higher Quality of Life (QoL)).

1861 Trial patients who did not survive to 30 days/hospital discharge will be assigned EQ-5D visual analogue scale
1862 and summary index scores of zero.

1863

1864 **5.4 Other variables**

New variable	Rules
POPULATION 0 and 1:	
Age	If date of birth ≠ missing: Age= (OHCA date – Date of birth) /365.25 If date of birth = missing: Age= approximate age (see section 4) Else missing
999 call to first crew arrival time (mins)	(First crew arrival date-incident date)*24*60 + (First crew arrival time-incident time)
POPULATION 1:	
Trial patient	If was resuscitation attempted=Yes and was incident attended by AIRWAYS-2 paramedic=Yes and did patient meet eligibility criteria=Yes, then = Yes

New variable	Rules
Survival status to hospital discharge	<p>If was resuscitation attempted=No or was incident attended by AIRWAYS-2 paramedic=No or did patient meet eligibility criteria=No, then = No</p> <p>Else missing</p> <p>If admitted to ED (Form D)=No, then = Died on scene</p> <p>If admitted to ED=Yes, and survived to ICU admission (Form G)=No, then = Died prior to ICU admission</p> <p>If admitted to ED=Yes, and survived to ICU admission=Yes, and survived to ICU discharge (Form G)=No, then = Died prior to ICU discharge</p> <p>If admitted to ED=Yes, and survived to ICU admission=Yes, and survived to ICU discharge (Form G)=Yes, and transferred=Yes and level of care in transferred hospital (form G2)=Level 3 and survived to ICU discharge (Form G2)= No, then = Died prior to ICU discharge</p> <p>If admitted to ED=Yes, and survived to ICU admission=Yes, and survived to ICU discharge=Yes and ((transferred = No) or (transferred=Yes and level of care admitted to is level 2 or 1) or (transferred=Yes and level of care admitted to is level 3 and survived to ICU discharge=Yes)) and (mRS (Form H2/I2)=6 or (mRS (Form H2/I2) ≠6 & has patient died since ICU discharge (but prior to hospital discharge) (Form W2) = Yes) or survived to hospital discharge (form H3/I3)=No), then = Died prior to hospital discharge</p> <p>If admitted to ED=Yes, and survived to ICU admission=Yes, and survived to ICU discharge=Yes and ((transferred = No) or (transferred=Yes and level of care admitted to is level 2 or 1) or (transferred=Yes and level of care admitted to is level 3 and survived to ICU discharge=Yes)) and (mRS≠6 or survived to hospital discharge=Yes, then = Survived to 30 days/hospital discharge)</p>
Date of death	<p>If survival status=died on scene, then = Date resus stopped (Form E1)</p> <p>If survival status=died prior to ICU admission, then = Date of death 1 (Form G)</p> <p>If survival status=died prior to ICU discharge and survived to ICU discharge (Form G)=No, then = Date of death 2 (Form G)</p> <p>If survival status=died prior to ICU discharge and survived to ICU discharge (Form G2)=No, then = Date of death 3 (Form G2)</p> <p>If survival status=died prior to hospital discharge & consent status=active or passive, then = death date (Form H/I3)</p> <p>If survival status=died prior to hospital discharge & consent status≠active & consent status≠passive, then = death2 date (Form W2)</p> <p>If survival status=survived to 30 days/hospital discharge & has patient died since hospital discharge=Yes, then = death3 date (Form W2)</p> <p>Else missing</p>
Time of death	<p>If survival status=died on scene, then = Time resus stopped (Form E1)</p> <p>If survival status=died prior to ICU admission, then = Time of death 1 (Form G)</p> <p>If survival status=died prior to ICU discharge and survived to ICU discharge (Form G)=No, then = Time of death 2 (Form G)</p> <p>If survival status=died prior to ICU discharge and survived to ICU discharge (Form G2)=No, then = Time of death 3 (Form G2)</p> <p>If survival status=died prior to hospital discharge & consent status=active or passive, then = Time of death (Form H/I3)</p>

New variable	Rules
Time to death	<p>If survival status=died prior to hospital discharge & consent status≠active and status≠passive, then = 12 midnight</p> <p>If survival status=survived to 30 days/hospital discharge & has patient died since hospital discharge=Yes, then = 12 midnight</p> <p>(we do not collect time of death for patients who died after ICU discharge and do not consent to any follow-up or for patients who consent to active follow-up but died after hospital discharge)</p> <p>Else missing</p> <p><i>For patients who die prior to admission, in hospital, or during the follow up period:</i></p> <p>(Date of death – Incident date (Form A))*24*60 + (Time of death – Incident time (Form A))</p> <p><i>For patients who survive to 30 days/hospital discharge & consent to active follow-up and provides 6 month follow-up data (i.e. censored at 6 months post discharge for analysis)=</i></p> <p>(6m follow-up date (Form K-Cover) - Incident date (Form A)) *24*60 + (12 midday - Incident time (Form A))</p> <p><i>For patients who survive to 30 days/hospital discharge & consent to active follow-up and provides 3 month follow-up data but not 6 month follow-up data (i.e. censored at 3 months post discharge for analysis)=</i></p> <p>(3m follow-up date (Form K-Cover) - Incident date (Form A)) *24*60 + (12 midday - Incident time (Form A))</p> <p><i>For patients who survive to 30 days/hospital discharge & consent to passive follow-up or consented to active follow-up but do not provide any 3 or 6 month data (i.e. censored at hospital discharge for analysis)=</i></p> <p>(Hospital discharge date (Form H/I3) - Incident date (Form A)) *24*60 + (Hospital discharge time (Form H/I3) - Incident time (Form A))</p> <p><i>For patients who survive to (30 days or) hospital discharge & did not consent to active or passive follow-up (i.e. censored at ICU discharge for analysis) =</i></p> <p>(ICU discharge date (Form G) - Incident date (Form A)) *24*60 + (ICU discharge time Form G) - Incident time (Form A))</p> <p><i>Note – if time to death exceeds 183 days, then it will be censored at 183 days</i></p>
Time to death event/censor variable	<p>If (survival status≠survived to 30 days/hospital discharge & survival status≠missing) or has patient died since hospital discharge=Yes, then = 0</p> <p>If survival status=survived to 30 days/hospital discharge & (has patient died since hospital discharge=No or missing), then = 1</p> <p>Else missing</p> <p><i>Note – if time to death exceeds 183 days, then it will be censored at 183 days</i></p>
72 hour survival	<p>if time to death≥72 hours, then = Yes</p> <p>if time to death<72 hours & time to death censor variable=0, then = No</p> <p>if time to death<72 hours & time to death censor variable=1 & (mRS date-incident date) >3 & mRS at 30 days/discharge≠6, then = Yes</p> <p>Else missing</p>
Time to death: 0 to 72h	<p>if time to death≥72 hours, then = 72h</p> <p>if time to death<72 hours & time to death censor variable=0 (patient died), then = time to death</p>

New variable	Rules
	if time to death < 72 hours & time to death censor variable = 1 (censored) & ((30 day/discharge mRS date - incident date) > 3 & mRS at 30 days/discharge ≠ 6), then = 72h
	if time to death < 72 hours & time to death censor variable = 1 (censored) & ((30 day/discharge mRS date - incident date) ≤ 3 & mRS at 30 days/discharge ≠ 6), then = time to death
	Else missing
Time to death event/censor variable: 0 to 72h	if time to death ≥ 72 hours, then = 1 if time to death < 72 hours & time to death censor variable = 0 (patient died), then = 0 if time to death < 72 hours & time to death censor variable = 1 (censored), then = 1 Else missing
First crew arrival to first A2 paramedic arrival (mins)	(First A2 arrival date - First crew arrival date) * 24 * 60 + (First A2 arrival time - First crew arrival time)
Time of 999 call to first A2 paramedic arrival (mins)	(First A2 arrival date - Incident date) * 24 * 60 + (First A2 arrival time - Incident time)
Time between incident and discharge/30 day mRS measurement (days)	(mRS date - incident date) if measured face-to-face Else missing
Event witnessed by	if event witnessed by = non-ambulance staff (Form E1) or (event witnessed by = missing (Form E1) and event witnessed by = bystander (Form B)), then = bystander If event witnessed by = AIRWAYS-2 paramedic or ambulance staff (Form E1) or (event witnessed by = missing (Form E1) and event witnessed by = EMS (Form B)), then = EMS Else missing
Utstein comparator group	if event witnessed by = bystander and presenting rhythm = VF or pulseless VT, then = Yes if (event witnessed by = bystander and presenting rhythm = Asystole OR PEA OR unknown) or event witnessed by = EMS, then = No Else missing
Protocol deviation 1: consciously enrolled but ineligible	if consciously enrolled = Yes AND trial patient = No, then = Yes if trial patient = Yes, then = No Else missing
Protocol deviation 2: wrong paramedic enrolling patient	if Paramedic AIRWAYS-2 ID (Form A) ≠ Paramedic AIRWAYS-2 ID (Form E1) and Paramedic AIRWAYS-2 ID (Form E1) ≠ missing and trial patient = Yes, then = Yes if Paramedic AIRWAYS-2 ID (Form A) = Paramedic AIRWAYS-2 ID (Form E1) and Paramedic AIRWAYS-2 ID (Form E1) ≠ missing and trial patient = Yes, then = No
Protocol deviation 2: wrong paramedic enrolling patient resulting in allocation crossover	if protocol deviation 2 = Yes and allocation of enrolling paramedic ≠ allocation of first A2 paramedic on scene, then = Yes if protocol deviation 2 = Yes and allocation of enrolling paramedic = allocation of first A2 paramedic on scene, then = No Else missing
Protocol deviation 3:	if 'If no [airways management attempt completed on CRF E2], why?' = Further airway management commenced once A2 paramedic arrived but not carried out by enrolling A2 paramedic and trial patient = Yes, then = Yes

New variable	Rules
	if 'has at least one airway management attempt recorded on CRF E2?' ≠ missing and 'If no [airways management attempt completed on CRF E2], why?' ≠ Further airway management commenced once A2 paramedic arrived but not carried out by enrolling A2 paramedic and trial patient = Yes, then = No Else missing
Protocol deviation 4	if (Paramedic allocated to i-gel and first advanced airways management attempt is intubation or other SGA) or (Paramedic allocated to intubation and first advanced airways management attempt is i-gel or other SGA and paramedic is not a solo responder), then = Yes if first advanced airway management attempt matches paramedic allocation, then = No Else missing (including patients with no advanced airways management attempts)
Protocol deviation 5	if (paramedic allocated to i-gel and number of i-gel attempts made before switching to intubation or other SGA = 1 or (paramedic allocated to intubation and number of intubation attempts made before switching to i-gel or other SGA = 1), then = Yes if (paramedic allocated to i-gel and number of i-gel attempts made before switching to intubation or other SGA ≠ 1 and at least one advanced airways management attempt recorded) or (paramedic allocated to intubation and number of intubation attempts made before switching to i-gel or other SGA ≠ 1 and at least one advanced airways management attempt recorded), then = No Else missing
POPULATION 2:	
Initial ventilation success in first or second attempt	If i-gel is used before intubation or other SGA: If ventilation success = yes on first i-gel attempt, then = Yes If ventilation success = no on the first i-gel attempt and the next advanced attempt is also i-gel and on that attempt ventilation success = yes, then = Yes If ventilation success = no on first i-gel attempt and the next advanced attempt is also i-gel and ventilation success = no, then = No If ventilation success = no on first i-gel attempt and (there is no further attempt or the next advanced attempt is intubation or other SGA), then = No If intubation is used before i-gel or other SGA: If ventilation success = yes on first intubation attempt, then = Yes If ventilation success = no on the first intubation attempt and the next advanced attempt is also intubation and on that attempt ventilation success = yes, then = Yes If ventilation success = no on first intubation attempt and the next advanced attempt is also intubation and ventilation success = no, then = No If ventilation success = no on first intubation attempt and (there is no further attempt or the next advanced attempt is i-gel or other SGA), then = No If other SGA is used before i-gel or intubation:

New variable	Rules
	<p>If ventilation success= yes on first other SGA attempt, then = Yes</p> <p>If ventilation success = no on the first other SGA attempt and the next advanced attempt is also other SGA and on that attempt ventilation success = yes, then = Yes</p> <p>If ventilation success = no on first other SGA attempt and the next advanced attempt is also other SGA and ventilation success = no, then = No</p> <p>If ventilation success = no on first other SGA attempt and (there is no further attempt or the next advanced attempt is i-gel or intubation), then = No</p> <p>Else missing</p>
Any ventilation success	<p>If ventilation success=Yes for any advanced airway management attempts on Form E2, then = Yes</p> <p>If ventilation success=No for all advanced airway management attempts on Form E2, then = No</p> <p>Else missing</p>
Any loss of previously established airway <i>(only calculated if any ventilation success=Yes)</i>	<p>If ‘if an airway was established, was it later lost’=Yes for any advanced airway management attempts on Form E2, then = Yes</p> <p>If (‘if an airway was established, was it later lost’=No OR ‘ventilation success’=No) for all advanced airway management attempts on Form E2, then = No</p> <p>Else missing</p>
Actual sequence of airway interventions delivered	<p>If at least one airway management attempted:-</p> <p>A six digit code will be derived from the airway management type (1=OPA, 2=NPA, 3=i-gel, 4=intubation, 5=other SGA, 6=other) used at the first to the 6th airway management attempt, using the following:</p> <p>Code = 100000*1st attempt airway management type + 10000*2nd attempt airway management type + 1000*3rd attempt airway management type + 100*4th attempt airway management type + 10*5th attempt airway management type + *6th attempt airway management type</p> <p>If no airways management attempted, = missing</p>
Any ROSC during airway management	<p>If ‘was ROSC achieved’=Yes for any advanced airway management attempts on Form E2, then = Yes</p> <p>If ‘was ROSC achieved’=No for all advanced airway management attempts on Form E2, then = No</p> <p>Else missing</p>
Airway management in place when first ROSC was achieved or the resuscitation was discontinued if no ROSC was achieved	<p>if (‘any ROSC achieved during airway management’=Yes and airway management first time ROSC was achieved=intubation) OR (‘any ROSC achieved during airway management’=No and final airway attempt=intubation and ‘was airway management handed over’=No), then = intubation</p> <p>if (‘any ROSC achieved during airway management’=Yes and airway management first time ROSC was achieved= i-gel) OR (‘any ROSC achieved during airway management’=No and final airway attempt= i-gel and ‘was airway management handed over’=No), then = i-gel</p>

New variable	Rules
	<p>if ('any ROSC achieved during airway management'=Yes and airway management first time ROSC was achieved= any SGA) OR ('any ROSC achieved during airway management'=No and final airway attempt= any SGA and 'was airway management handed over'=No), then = other SGA if ('any ROSC achieved during airway management'=Yes and airway management first time ROSC was achieved=OPA/NPA) OR ('any ROSC achieved during airway management'=No and final airway attempt= OPA/NPA and 'was airway management handed over'=No), then = other Else missing</p>
POPULATION 3:	
Duration of initial ICU stay	<p><i>For patients who survive to ICU discharge in admitting hospital and (were not transferred or were transferred to another hospital but at a lower level of care) =</i> (ICU discharge date - ICU admission date)*24*60 + (ICU discharge time - ICU admission time)</p> <p><i>For patients who are transferred from ICU in the admitting hospital to ICU (level 3 care) in another hospital and survives to ICU discharge in the transferred hospital =</i> ((ICU discharge date on Form G2 - ICU admission date on Form G)*24*60 + (ICU discharge time on Form G2- ICU admission time on form G))</p> <p><i>For patients who die in ICU in the admitting hospital (i.e. censored for analysis) =</i> (ICU death date - ICU admission date)*24*60 + (ICU death time - ICU admission time)</p> <p><i>For patients who are transferred from ICU in the admitting hospital to ICU (level 3 care) in another hospital and die in ICU in the transferred hospital (i.e. censored for analysis) =</i> ((ICU death date on form G2 - ICU admission date on form G)*24*60 + (ICU death time on form G2 - ICU admission time on form G))</p>
ICU duration event/censor variable	<p>If survived to ICU discharge =Yes and transferred= No on form G, then = 1 If survived to ICU discharge =Yes and transferred= Yes on form G and survived to ICU discharge =Yes on form G2, then = 1 If survived to ICU discharge=No on form G, then = 0 If survived to ICU discharge =Yes and transferred= Yes on form G and survived to ICU discharge =No on form G2, then = 0 Else missing</p>
POPULATION 4:	
Duration of hospital stay	<p>If survival status = survived to 30 days/hospital discharge and consent=active or consent=passive, then = (Hospital discharge date (Form H/I3) - ED admission date (Form G)) *24*60 + (Hospital discharge time (Form H/I3) - ED admission time (Form G))</p>

New variable	Rules
	<p>If survival status= died prior to ICU admission or survival status= died prior to ICU discharge or (survival status=died prior to hospital discharge & ((consent status=active or passive) or patient was not approached)), then = (Date of death - ED admission date (Form G)) *24*60 + (Time of death - ED admission time (Form G)) Else missing</p>
Hospital duration event/censor variable	<p>If survival status =survived to 30 days/ hospital discharge and consent=active or consent=passive, then = 1 If survival status= died prior to ICU admission or survival status= died prior to ICU discharge or (survival status=died prior to hospital discharge & ((consent status=active or passive) or patient was not approached)), then = 0 Else missing</p>
Timing of (patient) withdrawal	<p>if date of withdrawal from study < date of discharge, then = pre-discharge if date of withdrawal from study > date of discharge, then = post-discharge Else missing</p>
Decision taken by	<p>if healthcare professional's decision=Yes and (patient choice = No or missing), then = health care professional if healthcare professional's decision=No or missing and patient choice = Yes, then = patient Else missing</p>

1865

1866

1867 **6. STATISTICAL ANALYSES**

1868 **6.1 Baseline data**

1869 Baseline characteristics (i.e. patient demography and initial cardiac arrest details) will be described grouped
1870 by the allocation of the first A2 paramedic on scene for all trial patients (see **Table T4**). Intervention details
1871 will also be described for all trial patients (see **Table T5**).

1872 Continuous variables will be summarised using the mean and standard deviation (SD) (or median and inter
1873 quartile range (IQR) if the distribution is skewed), and categorical data will be summarised as a number and
1874 percentage. The summary statistic headings given in **Tables T4** and **T5** are those we expect to use based on a-
1875 priori knowledge of the clinical measurements gained from previous studies. However, if distributional
1876 assumptions are not satisfied, changes will be made.

1877 Statistical tests to compare data not listed as outcomes will not be performed. Secondary outcomes 4
1878 (sequence of airway interventions delivered) and 7 (airway management in place when ROSC was achieved
1879 or resuscitation discontinued) will be described but not formally compared.

1880 **6.2 Primary and secondary outcome data**

1881 **6.2.1 Adjustment in models**

1882 The intention is to adjust the models for the three stratification (design) factors: ambulance trust (four levels),
1883 clinical experience (two levels) and the location of the paramedic’s base ambulance station (two levels) as
1884 fixed effects, and paramedic as a random effect (or a shared frailty term in the time to event model). For the
1885 mRS model where the majority of patients will have a poor outcome/death, the data may be insufficient to
1886 allow estimation of regression coefficients for all these variables. If this is the case, inestimable stratification
1887 variables will be dropped from the model and will be noted in a footnote. For the time to death model, if a cox
1888 model is used the analysis will be stratified by trust (to allow for varying baseline hazards) and adjusted for
1889 the other design factors. If either of the design factors do not meet the proportional hazards assumptions,
1890 stratification by these factors will also be implemented.

1891 **6.2.2 Data presentation and analysis models**

1892 For intention to treat analyses, data will be presented and analysed by the allocated group of the first A2
1893 paramedic on scene, regardless of what airway management the patient received. For per-protocol analyses
1894 (see sections 6.2.5 and 6.2.6), data will be presented and analysed by the allocation of the first advanced
1895 airway management used; if neither i-gel nor intubation was used (or if another SGA was used before an i-gel
1896 or intubation), the patients will be excluded from per-protocol analyses.

1897 All analyses and data presentation will be by intention to treat unless otherwise stated in the Table heading.

1898 All outcomes listed in Sections 2.3 and 2.4 will be presented as per the template tables **Table T6** to **T8** and
1899 may also be presented graphically. General methods of presentation and assessing intervention effects are
1900 outlined below. For formal comparisons the intubation group will be the reference group. Details specific to
1901 each outcome are described as appropriate. Secondary outcomes 10 to 13 will not be reported in the primary
1902 outcome paper.

Date type	Outcomes
Binary	mRS (at discharge/30days) Initial ventilation success Regurgitation/aspiration Loss of previously established airway Return of spontaneous circulation (ROSC) 72h survival
Categorical	Actual sequence of airway interventions delivered ¹ Airway management in place when ROSC was achieved or resuscitation was discontinued or intervention from A2 paramedic stopped ¹
Continuous	Chest compression fraction

	Duration of ICU stay (presented separately for survivors and patients who die during ICU stay) ¹
	Duration of hospital stay (presented separately for survivors and patients who die during hospital stay) ¹
Time to event	Time from OHCA to when discharge/30 day mRS was assessed ^{1,3} Time to death ² Time to death (up to 72h)
Longitudinal	mRS (at discharge/30days, 3 months and 6 months) EQ-5D index score and visual analogue scale score (at discharge, 3 months and 6 months)

1903 *Note:-*

1904 ¹ These outcomes will be described but not formally compared

1905 ² Time to death will be formally compared in place of length of ICU and hospital stay

1906 ³ This is not a specified outcome but the DMSC raised it as a point of interest.

1907

1908 • **Binary outcomes** will be presented as numbers and percentages of patients in the category of interest.
1909 Outcomes will be compared between intervention groups using logistic regression. The intervention
1910 comparison estimate will be presented as an adjusted odds ratio (OR) with a 95% confidence interval
1911 (95% CI) and p-value. Formal statistical comparisons of treatment effects will only be performed if more
1912 than ten patients in total experience the outcome (with at least one event in each treatment group). .

1913 • **Categorical outcomes** will be presented as numbers and percentages of patients in each category.
1914 Outcomes will be compared between intervention groups using multinomial logistic regression.
1915 Treatment comparison estimates will be presented as adjusted odds ratios (OR) and 95% confidence
1916 intervals (95% CI). .

1917 • **Continuous outcomes** will be summarised by means and SDs in each treatment group, if distributions
1918 are approximately normal. If distributions are non-normal data will be summarised by the median and
1919 IQR or geometric mean (GM) if a logarithmic transformation provides an approximately normal
1920 distribution. Outcomes will be compared using linear regression. For untransformed data treatment
1921 comparisons will be presented as adjusted differences in means with 95% CI, and for logarithmically
1922 transformed data as adjusted ratios of GMs with 95% CI. Due to the large numbers of trial patients not
1923 expected to survive to 30 days/hospital discharge, a two-part zero-inflated modelling approach will also
1924 be considered for EQ5D visual analogue scale and summary index scores. This will comprise a) an
1925 occurrence model, a logistic regression model for the occurrence of death vs survival; b) intensity model,
1926 a log-linear model for the score, conditional on survival. If it is not possible to fit the model, then an
1927 analysis restricted to those who survive to hospital discharge will be considered.

1928 • **Time to event outcome** time to death will be summarised by the median and IQR in each intervention
1929 group. This will be compared using Cox's proportional hazards or parametric models as appropriate. The
1930 choice of model to use will depend on the distribution of the data. The intervention comparison will be
1931 presented as a hazard ratio (HR) and 95% CI if a proportional hazards model is used or time ratios (TR)
1932 and 95% CI if an accelerated failure time (AFT) model is used. Times will be censored at last contact for
1933 patients known to be alive at that time.

1934 • **Longitudinal outcomes** will be summarised for each time point. Binary and continuous outcomes will
1935 be compared using logistic and linear mixed effects methodologies respectively, with the treatment group
1936 and study design variables (see section 6.2.1) fitted as fixed effects, and patient terms as random effects.
1937 If a time x treatment interaction is not statistically significant at the 10% level an overall treatment effect
1938 will be reported. If the interaction is statistically significant the changes in treatment effect with time will
1939 be described. Different variance/covariance structures will be explored, and the structure that provides
1940 the best fit in terms of information criteria such as AIC, BIC and likelihood ratio tests will be used.

1941 **6.2.3 Statistical significance**

- 1942 For hypothesis tests two-tailed p-values < 0.05 are considered statistically significant.
- 1943 **6.2.4 Model assumptions**
- 1944 For all methods outlined underlying assumptions will be checked using standard methods, e.g. residual plots,
1945 tests for proportional hazards, etc. If assumptions are not valid then alternative methods of analysis will be
1946 sought. If outlying observations are found which mean models do not fit the data adequately, such
1947 observations will be excluded from the main analyses and comments made in footnotes.
- 1948 **6.2.5 Subgroup analyses**
- 1949 Two subgroup analyses for the primary outcome are specified in the protocol: Utstein comparator group vs
1950 non-comparator group and arrest witnessed by ambulance staff or not (**Figure F7**).
- 1951
- 1952 Due to concerns regarding ventilation success raised during the trial, a subgroup analysis of the primary
1953 outcome comparing patients whose i-gel or intubation airway management attempt(s) were or were not
1954 ‘successful’ during the first and/or second attempt (see section 5.2 for definition) will also be performed. This
1955 analysis will be performed per-protocol and as such will only include patients who received at least one
1956 advanced airway management attempt using an i-gel and/or intubation tube.
- 1957
- 1958 Subgroup effects will be fitted by adding a “sub-group x intervention” interaction term to the analysis model.
- 1959 **6.2.6 Sensitivity analyses**
- 1960 For the primary outcome, the following sensitivity analyses will be performed:
- 1961
 - ITT analysis including only patients who received at least one advanced airway management attempt
1962 using an i-gel and/or intubation tube.
 - Per-protocol analysis including only patients who received at least one advanced airway management
1963 attempt using an i-gel and/or intubation tube (see section 6.2.5 for additional sub-group analysis for
1964 this outcome).
 - ITT analysis including all patients who were attended by an AIRWAYS-2 paramedic but not
1965 resuscitated.
- 1966
- 1967
- 1968 **6.2.7 Missing data**
- 1969 In all tables missing data will be indicated by footnotes. If the amount of missing data differs substantially
1970 between treatment groups potential reasons will be explored.
- 1971 Missing predictors:
- 1972 There will be no missing data for any of the randomisation factors (by design).
- 1973 Missing outcomes:
- 1974
 - If the proportion of missing data is less than 5% then complete case analysis will be performed (i.e.
1975 excluding cases with missing data).
 - If the proportion of missing data is above 5% multiple imputation methods will be considered. A general
1976 imputation model that uses an iterative procedure to generate imputed values will be used to generate
1977 multiple complete data sets (e.g. using Stata’s mi impute). The model of interest will be the fitted to each
1978 of the complete data sets and effect estimates combined using Rubin’s rules.
- 1979
- 1980 If appropriate (the level of missingness is >20%) then any variables that are predictive of missingness will be
1981 identified, and if there is reason to suggest that an assumption of missing at random (MAR) given these
1982 variables is reasonable then such variables will be adjusted for in the models of interest. These models can be
1983 shown to provide unbiased estimates of the treatment effect and moreover multiple imputation approaches
1984 would not be expected to recover any additional information.
- 1985 **6.2.8 Multiple testing**
- 1986 No formal adjustment will be made for multiple testing. However as previously described formal statistical
1987 comparisons will not be made for outcomes with low event rates and only pre-specified subgroup analyses

1988 will be performed. Consideration will be taken in interpretation of results to reflect the number of statistical
1989 tests performed and the consistency, magnitude and direction of treatment estimates for different outcomes.

1990 **6.3 Safety data**

1991 Safety data are only collected for events which are unexpected and potentially related to the intervention. All
1992 such events will be detailed along with descriptions of patients' airway management pathway. **Table T9**
1993 summarises such events, as captured via serious adverse event (SAE) report forms and full details will also be
1994 given as listings (see **Table T10**).

1995 No formal comparisons between groups will be made as numbers of events are expected to be small.

1996

1997 **7. AMENDMENTS TO THE SAP**

Previous version	Previous date	New version	New date	Brief summary of changes
V1.0	14/02/2018	V2.0	14/04/2018	<p>Clarified definition of enrolling paramedic to better reflect the protocol and how it is defined in the analysis code – rephrased as “first A2 paramedic on scene” throughout.</p> <p>Corrected typographical errors and updated figure numbers as a figure added to aid interpretation of the data (new Figure F6).</p> <p>Changed ‘Incident (999 call) to first crew arrival (mins)’ to ‘999 call to first crew arrival (mins)’ throughout at the suggestion of the DMSC and TSC.</p> <p>Corrected inconsistent naming of survival status in data derivations.</p> <p>Added new variable ‘Time of 999 call to first A2 paramedic arrival (mins)’ at the suggestion of the DMSC and TSC (Table T4).</p> <p>Added a sentence to clarify what will be reported in the primary outcome paper.</p> <p>For the analysis of the EQ-5D outcomes the following was added ‘If it is not possible to fit the model, then an analysis restricted to those who survive to hospital discharge will be considered.’ to the allow for the fact that the two part model may not be estimable due to the high proportion of deaths.</p> <p>Labelling of tables was clarified and errors in labelling data types (viz. n/% vs. mean/SD or median /IQR) corrected.</p> <p>Figure F1 was revised to improve readability at the suggestion of the</p>

				<p>DMSC and TSC. A skeleton footnote was added to the revised figure.</p> <p>Added a breakdown of the numbers by group (rather than Trust) in Figure F2. Added a category to the list of reasons for non-approach.</p> <p>Revised Table T1 to increase readability – information presented in column with no descriptive data available was moved to a footnote. Merged the columns ‘Resuscitation attempted, attended by A2, but not eligible’ ‘trial patients’ at the suggestion of the DMSC and TSC.</p> <p>Removed ‘Enrolling paramedic made only one attempt at allocated intervention before swapping’ from Table T2 as this is not considered a protocol deviation.</p> <p>In Table T5, changed ‘Reasons for not receiving airway management’ to ‘Reasons for not reporting at least one airway management attempt’ for clarity.</p>

1998
1999
2000

2001
2002


APPENDIX A: SKELETON TABLES AND FIGURES

Section	Outputs
Section 1 Population	Tables, figures and listings detailing the study population Figure F1 Flow of participants Figure F2 Flow of patients Figure F3 Predicted and actual recruitment Figures F4 & F5 Predicted and actual recruitment by trust Table T1 Initial cardiac arrest details by enrolment status Table T2 Protocol deviations Table T3 Withdrawals
Section 2 Baseline and intervention data	Summary tables of demographic information Table T4 Patient demography and cardiac arrest details Table T5 Intervention and post-intervention details Figure F6 Interventions received by paramedic allocation
Section 3 Primary and secondary outcome data	Summary data and group estimates for primary and secondary outcomes Table T6 Primary outcome Table T7 Secondary outcomes Table T8 Longitudinal secondary outcomes Figure F7 Subgroup analyses
Section 4 Safety data	Summary tables and listings of all adverse events and serious adverse events Table T9 Unexpected serious adverse events Table T10 Details of unexpected serious adverse events

2003

2004
2005

Figure F1 Flow of paramedics and patients



note:

¹ XXX patients (XXX intubation, XXX i-Gel) received at least one airway management attempt but did not receive i-Gel or intubation. These patients received another SGA.

² of the XXX paramedics who withdrew after randomisation, XXX attended an OHCA (XXX Intubation, XXX i-gel) and XXX had not attended an OHCA (XXX intubation, XXX i-gel). Of the former, XXX attended one or more trial patients (XXX Intubation, XXX i-gel). The median number of OHCA attended per withdrawn paramedic is XXX for Intubation (IQR=XXX) and XXX for i-gel (IQR=XXX). The median number of trial patients attended per withdrawn paramedic is XXX for Intubation (IQR=XXX) and XXX for i-gel (IQR=XXX).


³ XXX patients in the intubation arm and XXX patients in the i-gel arm withdrew prior to 3 months follow-up.

⁴ XXX patients in the intubation arm and XXX patients in the i-gel arm withdrew after 3 months and prior to 6 months follow-up.

2006
2007
2008
2009
2010


Figure F2

Flow of patients



2011

Figure F3 Predicted and actual recruitment




2012
2013

2014 **Figure F4 Predicted and actual recruitment by trust (SWAST and YAS)**



2015
2016 **Figure F5 Predicted and actual recruitment by trust (EMAS and EAST)**



2017

2018

Table T1 Initial cardiac arrest details by enrolment status

	EXCLUDED FROM STUDY					
	Resuscitation attempted but not attended by A2		Resuscitation attempted and attended by A2		Resuscitation attempted, attended by A2, and eligible. I.e. trial patients	
	(n=)		(n=)		(n=)	
	n	%	n	%	n	%
Age (median, IQR)						
Male gender						
999 call to first crew arrival time (mins; median, IQR)						
Presenting rhythm						
Asystole						
VF						
Pulseless VT						
PEA						
Unknown						
Event witnessed						
By EMS						
By bystander						
Bystander CPR						

2019

Note: XXX patients were attended by an A2 paramedic but were not resuscitated.

2020 **Table T2 Protocol deviations**

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
	n	%	n	%	n	%
<i>All trial patients</i>						
Wrong paramedic enrolled patient						
Resulted in randomised allocation crossover						
Enrolling paramedic did not perform any airway management but another paramedic did						
<i>Trial patients with at least one advanced airway management attempt performed</i>						
Enrolling paramedic did not perform allocated intervention on first advanced airway attempt						

Note. All patients grouped by the allocation of the first A2 paramedic on scene.

2021
2022
2023

2024 **Table T3 Withdrawals**

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
	n	%	n	%	n	%
Any withdrawal (paramedics)						
Decision taken by						
Study team						
Paramedic						
Reason for withdrawal						
Reason 1						
Reason 2						
.....						
Any withdrawal (trial patients)						
Timing of withdrawal						
Pre-discharge						
Post-discharge						
Decision taken by						
Health care professional						
Patient						
Reason for withdrawal						
Reason 1						
Reason 2						
...						
...						

Note. This form only applied to patients who consent to active or passive follow-up

2025
2026

2027

Table T4 Patient demography and cardiac arrest details

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
	n	%	n	%	n	%
DEMOGRAPHY						
Male gender						
Age (median, IQR)						
INITIAL CARDIAC ARREST DETAILS						
999 call to first crew arrival time (mins; median, IQR)						
First crew arrival to A2 arrival time (mins; median, IQR)						
999 call to A2 arrival time (mins; median, IQR)						
Presenting rhythm						
Asystole						
VF						
Pulseless VT						
PEA						
Arrest witnessed						
By EMS						
By bystander						
Bystander/responder CPR before response vehicle arrived						
Bystander/responder defibrillation before response vehicle arrived						
If yes, ROSC achieved						
ON ARRIVAL OF A2 PARAMEDIC						
Patient had ROSC on arrival						
Airway management in progress						
None						
BVM only						
OPA						
NPA						
I-gel						
Intubation						
Other SGA*						
Other*						
Successful ventilations ongoing						

* Details will be provided

2028

2029

2030

2031

Table T5 Intervention details (excluding secondary outcomes)

	Randomised to <i>intubation</i> (n=XX)		Randomised to <i>i-gel</i> (n=XX)		Overall (n=XX)	
	n	%	n	%	n	%
A2 AIRWAY MANAGEMENT DETAILS						
At least one airway management attempt reported by study paramedic						
Reasons for not reporting at least one airway management attempt						
Resuscitation successful/ceased						
Another paramedic managed airway						
Enrolling paramedic managed airway but cannot remember details						
Patient had a tracheostomy						
Other						
Patient received at least one advanced airway management attempt by an A2 paramedic						
Intubation						
I-gel						
Other SGA						
CO ₂ monitoring/ capnography used						
If no, reason:						
Unavailable						
Faulty equipment						
N/A- no advanced airway management						
If yes, type of CO ₂ monitoring						
Colour only						
Capnometry (number only)						
Capnography (waveform)						
Mechanical CPR used during resuscitation						
Airway management handed over during pre-clinical care						
If yes, to whom						
Doctor						
Nurse						
Paramedic						


2032

2033

2034

2035

Figure F6 Interventions Received By Paramedic Allocation



[1] XX additional patients received an alternative supraglottic airway device only. Of which XX (%) had a good mRS score, XX (%) had a bad mRS score, XX was missing mRS, and XX (%) had an mRS of 6.

[2] XX additional patients received an alternative supraglottic airway device only. Of which XX (%) had a good mRS score, XX (%) had a bad mRS score, XX was missing mRS, and XX (%) had an mRS of 6.

2068

Table T6 Primary outcome (mRS) and survival status

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Estimate ¹ (95% CI)	p-value
	n	%	n	%		
mRS (0 to 3; good recovery)					OR ²	
0 (no symptoms)						
1						
2						
3						
4						
5						
6 (deceased)						
Time from OHCA to time mRS was assessed (median, IQR)						
Survival status:						
Died on scene						
Died prior to ICU admission						
Died prior to ICU discharge						
Died prior to hospital discharge						
Survived to hospital discharge						
Time to death (hours; median, IQR)					HR ³	
Time to death 0-72h (hours; median, IQR)					HR	
72 hour survival					OR	

2069 ¹OR=Odds ratio, HR=Hazard ratio

2070 ²ICC

2071 ³ ICC

2072

2073

2074

Table T7 Secondary outcomes and related post-intervention details

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Estimate ¹ (95% CI)	p-value
	median	IQR	median	IQR		
Compression Fraction					MD/GMR	
	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Estimate ¹ (95% CI)	p-value
	n	%	n	%		
AIRWAY MANAGEMENT DETAILS						
Actual sequence of airway interventions delivered						
Sequence 1						
Sequence 2						
.....						
Initial ventilation success (first two attempts) of first advanced airway management						
Intubation						
I-gel						
Other SGA						
Total						
Any ventilation success						
Intubation						
I-gel						
Other SGA						
Total						
Any loss of previously established airway						
Intubation						
I-gel						
Other SGA						
Total						
Regurgitation before initial i-gel/intubation attempt					OR	
If yes, aspiration					OR	
Regurgitation during or after initial i-gel/intubation attempt					OR	
If yes, aspiration					OR	
Any ROSC during advanced A2 airway management					OR	


Any ROSC during any A2 airway management						
Advanced airway management in place when patient first had ROSC						
Intubation						
I-gel						
Other SGA						
Other						
Airway management in place on final attempt by A2 paramedic in those who died on scene						
Intubation						
I-gel						
Other SGA						
Other						
Airway management in place when patient first had ROSC or on final attempt by A2 paramedic in those who died on scene						
Intubation						
I-gel						
Other SGA						
Other						
Total						
Airway management in place on final attempt by A2 paramedic in those who were admitted to ED						
Intubation						
I-gel						
Other SGA						
Other						
	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Estimate¹	
	n	%	n	%	(95% CI)	p-value
ED STAY						
Admitted to ED/ hospital						
ROSC on ED/hospital admission						
Survived to ED discharge						
ICU STAY						
Admitted to ICU from ED						
Survived to ICU discharge						
Duration of initial ICU stay in patients who survived to ICU discharge (hours; median, IQR)						

Duration of ICU stay in patients who died in ICU (hours; median, IQR)
Duration of ICU stay in all patients admitted to ICU from ED (hours; median, IQR)



HOSPITAL STAY

Survived to hospital discharge
Duration of hospital stay in patients who survived to discharge (days; median, IQR)
Duration of hospital stay in patients who died before discharge (hours; median, IQR)
Duration of hospital stay in all patients admitted to ED (hours; median, IQR)



2075
2076
2077
2078
2079

¹OR=Odds ratio (from logistic or, where marked *, multinomial regression), MD=mean difference, GMR=Geometric mean ratio


Table T8 Longitudinal secondary outcomes

	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
	n	%	n	%	N	%
mRS (0 to 3; good recovery)						
Discharge/30 days						
3 months						
6 months						
Treatment*time interaction						
Overall						OR
	Randomised to intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
	n	%	n	%	N	%
EQ5D index score (median, IQR)						
Discharge/30 days						
3 months						
6 months						
Treatment*time interaction						
Overall						OR, GMR
EQ5D visual analogue scale score (median, IQR)						
Discharge/30 days						
3 months						
6 months						

Treatment*time interaction	
Overall	OR, GMR

2080
2081
2082
2083
2084
2085
2086
2087

Figure F7 Subgroup analyses (example for one subgroup analysis: event witnessed by ambulance staff)



2088
2089

Table T9 Unexpected serious adverse events

		Received Intubation first (n=XX)		Received i-gel first (n=XX)	
		n	%	n	%
Number of patients experiencing one or more SAEs					
Number of events					
<i>Brief description of events</i>					
Timing of events	Pre-surgery Post-surgery but pre-discharge Post-discharge				
Maximum intensity	Mild Moderate Severe				
Reason event classified as SAE	Resulted in death Is/was life threatening Resulted in persistent or significant disability/incapacity Prolonged ongoing hospitalisation/ caused hospitalisation Other				
Relatedness to intervention	Possibly related Probably related Definitely related				

2090
2091
2092
2093

Table T10 Details of unexpected serious adverse events

Study ID=	Intervention randomised to=	Interventions received=	Patient withdrawn from study (and when)=
OHCA date=	Hospital discharge date (if applicable)=	Death date (if applicable)=	Timing of SAE= Post-intervention but pre-discharge/ Post-discharge
Brief description of event=	Location=	Maximum intensity=	Relatedness=
SAE start date/time=	SAE resolution date/time=	Event resulted in death=	Event was life threatening=
Event resulted in persistent/significant disability/incapacity=	Event prolonged ongoing hospitalisation/resulted in hospitalisation=	Other reason for reporting as SAE (with details)=	
Initial report: full details	Initial report: action=	Initial report: other info=	
FUP 1: full details	FUP 1: action=	FUP 1: other info=	
FUP 2: full details	FUP 2: action=	FUP 2: other info=	

2094
2095
2096

2097
2098

APPENDIX B: INDIVIDUAL EQ5D QUESTION DATA

		Randomised to Intubation (n=XX)		Randomised to i-gel (n=XX)		Overall (n=XX)	
		n	%	n	%	n	%
MOBILITY							
Discharge/30 days	No problems walking about						
	Slight problems walking about						
	Moderate problems walking about						
	Severe problems walking about						
	Unable to walk about						
3 months	No problems walking about						
	Slight problems walking about						
	Moderate problems walking about						
	Severe problems walking about						
	Unable to walk about						
6 months	No problems walking about						
	Slight problems walking about						
	Moderate problems walking about						
	Severe problems walking about						
	Unable to walk about						
SELF-CARE							
Discharge/30 days	No problems with washing or dressing						
	Slight problems washing or dressing						
	Moderate problems washing or dressing						
	Severe problems washing or dressing						
	Unable to wash or dress						
3 months	No problems with washing or dressing						
	Slight problems washing or dressing						
	Moderate problems washing or dressing						
	Severe problems washing or dressing						
	Unable to wash or dress						
6 months	No problems with washing or dressing						
	Slight problems washing or dressing						
	Moderate problems washing or dressing						

	Severe problems washing or dressing Unable to wash or dress						
USUAL ACTIVITIES							
Discharge/30 days	No problems with usual activities Slight problems with usual activities Moderate problems with usual activities Severe problems with usual activities Unable to perform usual activities						
3 months	No problems with usual activities Slight problems with usual activities Moderate problems with usual activities Severe problems with usual activities Unable to perform usual activities						
6 months	No problems with usual activities Slight problems with usual activities Moderate problems with usual activities Severe problems with usual activities Unable to perform usual activities						
PAIN/DISCOMFORT							
Baseline	No pain or discomfort Slight pain or discomfort Moderate pain or discomfort Severe pain or discomfort Extreme pain or discomfort						
3 months	No pain or discomfort Slight pain or discomfort Moderate pain or discomfort Severe pain or discomfort Extreme pain or discomfort						
6 months	No pain or discomfort Slight pain or discomfort Moderate pain or discomfort Severe pain or discomfort Extreme pain or discomfort						
ANXIETY/DEPRESSION							
Baseline	Not anxious or depressed						

3 months	Slightly anxious or depressed					
	Moderately anxious or depressed					
	Severely anxious or depressed					
	Extremely anxious or depressed					
	Not anxious or depressed					
6 months	Slightly anxious or depressed					
	Moderately anxious or depressed					
	Severely anxious or depressed					
	Extremely anxious or depressed					
	Not anxious or depressed					
	Slightly anxious or depressed					
	Moderately anxious or depressed					
	Severely anxious or depressed					
	Extremely anxious or depressed					

2099
2100
2101